image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
818c4417228507708574b886d0fa0047239827ed7b3fe8f02a05d0ee83f71bc8.png | simple | <table><tr><td>Substrate</td><td>Enzymatic activity(mU/μL)</td><td>Specific activity(mU/mg)</td></tr><tr><td>Laminarin</td><td>0.049 ± 0.002</td><td>290 ± 30</td></tr><tr><td>CMC</td><td>0.010 ± 0.001</td><td>59 ± 8</td></tr><tr><td>Pectin</td><td>0.0008 ± 0.0001</td><td>5 ± 1</td></tr><tr><td>Xylan</td><td>0.034 ± 0.002</td><td>210 ± 20</td></tr><tr><td>pnPβGlu</td><td>0.020 ± 0.001</td><td>120 ± 10</td></tr><tr><td>pnPβXyl</td><td>0.013 ± 0.001</td><td>81 ± 9</td></tr><tr><td>Avicel</td><td>0.015 ± 0.001</td><td>90 ± 10</td></tr><tr><td>CSCB</td><td>0.032 ± 0.002</td><td>190 ± 21</td></tr></table> |
e8be84844a23c2e6eecb4e2e18ff4269559d360054e405393bd5c45fce33a1ea.png | complex | <table><tr><td rowspan="3">Parameters</td><td rowspan="3">Units</td><td colspan="4">Vinasse</td><td rowspan="2" colspan="2">Filter Cake (<i>n</i> = 9)</td><td rowspan="2" colspan="2">Bagasse (<i>n</i> = 9)</td><td rowspan="2" colspan="2">Straw (<i>n</i> = 12)</td><td rowspan="2" colspan="2">Recommendation</td></tr><tr><td colspan="2">Autonomous (<i>n</i> = 6)</td><td colspan="2">Annexed (<i>n</i> = 15)</td></tr><tr><td>AV</td><td>SD</td><td>AV</td><td>SD</td><td>AV</td><td>SD</td><td>AV</td><td>SD</td><td>AV</td><td>SD</td><td>[13]</td><td>[14]</td></tr><tr><td>TS <sup>a</sup></td><td>% FM <sup>d</sup></td><td>1.15</td><td>±0.12</td><td>3.44</td><td>±1.11</td><td>28.9</td><td>±3.77</td><td>55.4</td><td>±4.19</td><td>76.7</td><td>±21.6</td><td>-</td><td>-</td></tr><tr><td>VS <sup>b</sup></td><td>% TS</td><td>76.0</td><td>±6.99</td><td>70.6</td><td>±3.84</td><td>74.2</td><td>±10.8</td><td>96.0</td><td>±2.70</td><td>86.3</td><td>±11.9</td><td>-</td><td>-</td></tr><tr><td>COD <sup>c</sup></td><td>g·L<sup>−1</sup></td><td>22.1</td><td>±0.46</td><td>32.4</td><td>±10.0</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>C</td><td>% TS</td><td>37.0</td><td>±4.24</td><td>39.0</td><td>±8.61</td><td>42.7</td><td>±6.95</td><td>47.6</td><td>±2.69</td><td>43.4</td><td>±4.78</td><td rowspan="2">C:N 20–40:1</td><td>-</td></tr><tr><td>N</td><td>% TS</td><td>2.94</td><td>±0.35</td><td>2.31</td><td>±0.35</td><td>1.76</td><td>±0.24</td><td>0.41</td><td>±0.04</td><td>0.52</td><td>±0.21</td><td>-</td></tr><tr><td>P</td><td>% TS</td><td>0.16</td><td>±0.05</td><td>0.35</td><td>±0.12</td><td>0.60</td><td>±0.25</td><td>0.04</td><td>±0.02</td><td>0.06</td><td>±0.03</td><td rowspan="2">C:N:P:S 600:15:5:3</td><td>-</td></tr><tr><td>S</td><td>% TS</td><td>0.87</td><td>±0.49</td><td>2.12</td><td>±0.27</td><td>0.18</td><td>±0.02</td><td>0.05</td><td>±0.03</td><td>0.21</td><td>±0.06</td><td>-</td></tr><tr><td>Ca</td><td>mg·L<sup>−1</sup></td><td>77.4</td><td>±24.3</td><td>655</td><td>±211</td><td>4139</td><td>±1667</td><td>704</td><td>±215</td><td>2981</td><td>±1656</td><td>-</td><td>100–200</td></tr><tr><td>Na</td><td>mg·L<sup>−1</sup></td><td>16.4</td><td>±9.39</td><td>24.5</td><td>±9.58</td><td>7.75</td><td>±5.98</td><td>11.3</td><td>±8.83</td><td>37.1</td><td>±25.1</td><td>-</td><td>100–200</td></tr><tr><td>K</td><td>mg·L<sup>−1</sup></td><td>1306</td><td>±708</td><td>6021</td><td>±565</td><td>740</td><td>±280</td><td>1651</td><td>±1036</td><td>5002</td><td>±2344</td><td>-</td><td>200–400</td></tr><tr><td>Mg</td><td>mg·L<sup>−1</sup></td><td>173.6</td><td>±72.4</td><td>771</td><td>±177</td><td>971</td><td>±259</td><td>409</td><td>±173</td><td>1140</td><td>±404</td><td>-</td><td>75–150</td></tr></table> |
f2b8436a687dc46f0d11c4710090b23136ecd025ef351852da5cc2a056da2f4e.png | simple | <table><tr><td>Variables</td><td>Rank†</td><td>P-value</td><td>HR</td><td>95% CI</td></tr><tr><td>Age</td><td>5</td><td>0.60</td><td>0.9</td><td>0.5-1.6</td></tr><tr><td>Male</td><td>3</td><td>0.10</td><td>2.5</td><td>0.8-7.7</td></tr><tr><td>Black</td><td>6</td><td>0.82</td><td>1.1</td><td>0.3-3.8</td></tr><tr><td>Initial creatinine ≥ 175 μmol /L</td><td>1</td><td>0.00</td><td>6.1</td><td>2.2-17</td></tr><tr><td>Uncontrolled hypertension</td><td>2</td><td>0.01</td><td>4.3</td><td>1.4-14</td></tr><tr><td>Trombotic microangiopathy</td><td>4</td><td>0.19</td><td>1.9</td><td>0.7-5.2</td></tr></table> |
7d4c484f571f44defcf785b37ec15fbae066ed4c4ed38856d93e56d301ce0b80.png | simple | <table><tr><td>Gene locus</td><td>Control (fructose)</td><td>Xylose 1 hour</td><td>Xylose 4 hours</td><td>Xylose + glucose 1 hour</td><td>Xylose + glucose 4 hours</td></tr><tr><td>An06g00620</td><td>0.08 ± 0.03</td><td>0.42 ± 0.07</td><td>0.38 ± 0.05</td><td>0.003 ± 0.00</td><td>0.03 ± 0.01</td></tr><tr><td>An15g04270</td><td>0.05 ± 0.00</td><td>0.04 ± 0.00</td><td>0.20 ± 0.00</td><td>0.04 ± 0.00</td><td>0.02 ± 0.00</td></tr><tr><td>An15g05440</td><td>0.34 ± 0.04</td><td>0.24 ± 0.03</td><td>0.56 ± 0.12</td><td>0.09 ± 0.05</td><td>0.19 ± 0.05</td></tr><tr><td>An11g03700</td><td>0.06 ± 0.00</td><td>0.04 ± 0.01</td><td>0.17 ± 0.01</td><td>0.009 ± 0.001</td><td>0.05 ± 0.01</td></tr><tr><td>An12g09270</td><td>0.29 ± 0.04</td><td>0.20 ± 0.02</td><td>0.56 ± 0.03</td><td>0.010 ± 0.001</td><td>0.20 ± 0.05</td></tr><tr><td>An01g00850</td><td>0.25 ± 0.01</td><td>0.16 ± 0.03</td><td>0.60 ± 0.02</td><td>0.13 ± 0.01</td><td>0.45 ± 0.17</td></tr><tr><td>An06g00260</td><td>0.70 ± 0.03</td><td>2.40 ± 0.22</td><td>2.30 ± 0.64</td><td>0.25 ± 0.01</td><td>0.36 ± 0.07</td></tr></table> |
f5fdbe2034cd46eb929dfad7cda9a443d65175e8e3c5925b2a2949b22ec432d8.png | simple | <table><tr><td></td><td>Diploid, n (%)</td><td>Aneuploid, n (%)</td><td>p-value*</td></tr><tr><td>Age, quartiles</td><td></td><td></td><td></td></tr><tr><td> <58</td><td>178 (91)</td><td>18 (9)</td><td><0.001</td></tr><tr><td> 58 – 66</td><td>171 (83)</td><td>35 (17)</td><td></td></tr><tr><td> 66 – 75</td><td>145 (69)</td><td>66 (31)</td><td></td></tr><tr><td> ≥ 75</td><td>144 (68)</td><td>68 (32)</td><td></td></tr><tr><td>Histologic type and grade<sup>a</sup></td><td></td><td></td><td><0.001</td></tr><tr><td> Endometrioid, grade 1-2</td><td>467 (87)</td><td>71 (13)</td><td></td></tr><tr><td> Endometrioid, grade 3</td><td>75 (63)</td><td>44 (37)</td><td></td></tr><tr><td> Non-endometrioid</td><td>76 (51)</td><td>72 (49)</td><td></td></tr><tr><td>FIGO stage</td><td></td><td></td><td><0.001</td></tr><tr><td> Stage I</td><td>502 (81)</td><td>121 (19)</td><td></td></tr><tr><td> Stage II</td><td>54 (74)</td><td>19 (26)</td><td></td></tr><tr><td> Stage III</td><td>62 (66)</td><td>32 (34)</td><td></td></tr><tr><td> Stage IV</td><td>20 (57)</td><td>15 (43)</td><td></td></tr><tr><td>ER/PR status<sup>b</sup></td><td></td><td></td><td><0.001</td></tr><tr><td> ER and/or PR positive</td><td>389 (82)</td><td>84 (18)</td><td></td></tr><tr><td> ER and PR negative</td><td>72 (61)</td><td>46 (39)</td><td></td></tr></table> |
447c38f8d97d56527c2f5a0310624e6d9427041c31e7022cd83dbd5cfae83a6d.png | simple | <table><tr><td>Container capacity, L</td><td>Number of 2MR disks</td><td>Target ppb</td></tr><tr><td>10</td><td>1/5</td><td>27</td></tr><tr><td>20</td><td>1⁄2</td><td>27</td></tr><tr><td>30</td><td>2/3</td><td>27</td></tr><tr><td>40</td><td>1</td><td>27</td></tr><tr><td>50</td><td>1</td><td>27</td></tr></table> |
e48b1bf6d1ba18a2ddb0b8d96713850ff0f1934e90ff54420c32fc423afbbd38.png | simple | <table><tr><td>Variable</td><td>B</td><td>SE</td><td>p</td><td>OR</td></tr><tr><td>Theme B vs all others</td><td>3.260</td><td>.744</td><td>.017</td><td>4.64</td></tr><tr><td>having some TFA questions</td><td>2.816</td><td>.757</td><td><.001</td><td>16.71</td></tr><tr><td>constant</td><td>-5.515</td><td>.841</td><td><.001</td><td>.004</td></tr></table> |
06229a79b4c3ee4f59f1aa6c86d420006473534143898a34b40309bf65af56ff.png | simple | <table><tr><td>A</td><td>B</td><td>C</td><td>D</td><td>E</td><td>F</td><td>S</td><td>M</td><td>Range(where present)</td><td>Peak assignments<sup>*</sup></td></tr><tr><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1299</td><td>–</td><td>–</td><td>1299</td><td>(CH<sub>2</sub>)<sub><i>n</i></sub> deformations</td></tr><tr><td>–</td><td>–</td><td>–</td><td>–</td><td>1356</td><td>–</td><td>1355</td><td>–</td><td>1356</td><td>Tertiary (CH) deformation</td></tr><tr><td>1411</td><td>1415</td><td>1413</td><td>1413</td><td>1413</td><td>1415</td><td>–</td><td>–</td><td>1411–1415</td><td>(CH<sub>2</sub>) or (CH<sub>3</sub>)</td></tr><tr><td>–</td><td>1438</td><td>–</td><td>–</td><td>–</td><td>1439</td><td>–</td><td>–</td><td>1438–1439</td><td>(CH<sub>2</sub>)</td></tr><tr><td>1450</td><td>–</td><td>1443</td><td>1447</td><td>1447</td><td>1449</td><td>–</td><td>1445</td><td>1443–1450</td><td>(CH<sub>2</sub>), (CH)</td></tr><tr><td>1509</td><td>–</td><td>1509</td><td>1507</td><td>1511</td><td>–</td><td>1510</td><td>1510</td><td>1507–1511</td><td>Asymmetrical aryl ring stretch</td></tr><tr><td>1603</td><td>–</td><td>1603</td><td>1603</td><td>1602</td><td>1605</td><td>–</td><td>–</td><td>1602–1605</td><td>Aryl stretching vibration</td></tr><tr><td>1716</td><td>1724</td><td>1729</td><td>1724</td><td>1727</td><td>1719</td><td>1727</td><td>1728</td><td>1716–1729</td><td>C = O stretch of aldehydes, ketones, esters</td></tr><tr><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>2820</td><td>–</td><td>2820</td><td>CH bending</td></tr><tr><td>–</td><td>2851</td><td>2845</td><td>2856</td><td>2856</td><td>2850</td><td>–</td><td>–</td><td>2845–2856</td><td>CH antisymmetric and symmetric stretch of aliphatic compounds</td></tr><tr><td>–</td><td>2882</td><td>–</td><td>–</td><td>–</td><td>2881</td><td>–</td><td>–</td><td>2881–2882</td><td>CH antisymmetric and symmetric stretch of aliphatic compounds</td></tr><tr><td>2905</td><td>2907</td><td>2907</td><td>2908</td><td>2907</td><td>–</td><td>–</td><td>2909</td><td>2905–2909</td><td>CH antisymmetric and symmetric stretch of aliphatic compounds</td></tr><tr><td>–</td><td>2932</td><td>–</td><td>–</td><td>–</td><td>2932</td><td>–</td><td>2934</td><td>2932–2934</td><td>CH antisymmetric and symmetric stretch of aliphatic compounds</td></tr><tr><td>2939</td><td>–</td><td>–</td><td>2941</td><td>2938</td><td>2938</td><td>2939</td><td>–</td><td>2938–2941</td><td>Antisymmetric C–H stretch in –OCH<sub>3</sub> symmetric CH stretch</td></tr><tr><td>2963</td><td>2966</td><td>2966</td><td>2968</td><td>2966</td><td>2967</td><td>–</td><td>2969</td><td>2963–2969</td><td>CH antisymmetric and symmetric stretch of aliphatic compounds</td></tr><tr><td>3074</td><td>–</td><td>–</td><td>–</td><td>3073</td><td>–</td><td>–</td><td>–</td><td>3073–3074</td><td>(=C–H)</td></tr></table> |
426533f2e4abb9953dd37f8719f7cfce124aa1ca6642b2696e45bc952f3ac5b0.png | complex | <table><tr><td></td><td colspan="4">6-month change score</td><td rowspan="3">Difference of two groups (I – C)</td></tr><tr><td rowspan="2"></td><td colspan="2">Intervention Group</td><td colspan="2">Control Group</td></tr><tr><td>N*</td><td></td><td>N*</td><td></td></tr><tr><td>Laboratory data</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">HbA1c (% (mmol/l)</td><td rowspan="2">224</td><td>−1.0 (−1.2 to −0.7)</td><td>217</td><td>−0.5 (−0.8 to −0.3)</td><td>−0.4 (−0.8 to −0.1)</td></tr><tr><td>(−10.5 (−13.2 to −8.0))</td><td></td><td>(−5.9 (−8.7 to −3.2))</td><td>(−4.6 (−8.4 to −0.9))</td></tr><tr><td>Social support</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Social support score from Diabetes Care Profile (points)</td><td>222</td><td>0.2 (−0.0 to 0.4)</td><td>217</td><td>0.1 (−0.1 to 0.3)</td><td>0.1 (−0.2 to 0.4)</td></tr><tr><td>SF-12 Scores</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PCS-12 (points)</td><td>203</td><td>0.6 (−0.4 to 1.6)</td><td>196</td><td>1.6 (0.6 to 2.6)</td><td>−1.0 (−2.4 to 0.4)</td></tr><tr><td>MCS-12 (points)</td><td>203</td><td>1.4 (0.3 to 2.5)</td><td>196</td><td>−0.2 (−1.3 to 0.9)</td><td>1.6 (0.1 to 3.2)</td></tr><tr><td>Program evaluation (Post-intervention only)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Participants’ perception of empowerment attributable to the program at follow-up (points) †</td><td>226</td><td>4.4 (4.4 to 4.5)</td><td>216</td><td>4.3 (4.2 to 4.4)</td><td>0.1 (0.0 to 0.2)</td></tr></table> |
6901e09cc31bd81df12550167e7219a03987b6f999f8862ed83398a2721a41b5.png | simple | <table><tr><td> </td><td> </td><td>Value</td></tr><tr><td>Age (years)</td><td> </td><td>41 (18–79)</td></tr><tr><td>Gender (n)</td><td>Male</td><td>64</td></tr><tr><td> </td><td>Female</td><td>73</td></tr><tr><td>Marital status (n)</td><td>Single</td><td>26</td></tr><tr><td> </td><td>Married</td><td>111</td></tr><tr><td>Education (n)</td><td>Primary school</td><td>69</td></tr><tr><td> </td><td>Secondary school</td><td>17</td></tr><tr><td> </td><td>High school</td><td>31</td></tr><tr><td> </td><td>University</td><td>20</td></tr></table> |
f6f862563b1c5cb497cfa84a859f4b02fe4a00bd568182c50d3dff7cf22ee8f9.png | simple | <table><tr><td>Feature</td><td>B</td><td>W</td><td>A</td><td>W+A</td><td>LLQ (pg/mL)</td><td>ULQ (pg/mL)</td></tr><tr><td>AR</td><td>73</td><td>27</td><td>0</td><td>27</td><td>48</td><td>5599</td></tr><tr><td>BDNF</td><td>8</td><td>87</td><td>5</td><td>92</td><td>26</td><td>3956</td></tr><tr><td>Flt3Lig</td><td>2</td><td>98</td><td>0</td><td>98</td><td>17</td><td>9835</td></tr><tr><td>GCP-2</td><td>26</td><td>74</td><td>0</td><td>74</td><td>132</td><td>13153</td></tr><tr><td>HCC4</td><td>8</td><td>46</td><td>46</td><td>92</td><td>112</td><td>7907</td></tr><tr><td>I-309</td><td>30</td><td>70</td><td>0</td><td>70</td><td>20</td><td>5142</td></tr><tr><td>IL-17</td><td>95</td><td>5</td><td>0</td><td>5</td><td>330</td><td>7921</td></tr><tr><td>IL-1a</td><td>69</td><td>31</td><td>0</td><td>31</td><td>10</td><td>2943</td></tr><tr><td>IL-1b</td><td>46</td><td>54</td><td>0</td><td>54</td><td>4</td><td>2932</td></tr><tr><td>IL-2</td><td>89</td><td>7</td><td>4</td><td>11</td><td>31</td><td>3671</td></tr><tr><td>M-CSF</td><td>55</td><td>45</td><td>0</td><td>45</td><td>86</td><td>6761</td></tr><tr><td>MCP-1</td><td>17</td><td>69</td><td>14</td><td>83</td><td>82</td><td>2065</td></tr><tr><td>MIG</td><td>8</td><td>87</td><td>5</td><td>92</td><td>13</td><td>5030</td></tr><tr><td>MIP-1b</td><td>29</td><td>56</td><td>16</td><td>71</td><td>16</td><td>2399</td></tr><tr><td>MIP-1d</td><td>10</td><td>72</td><td>18</td><td>90</td><td>192</td><td>6969</td></tr><tr><td>NT-3</td><td>75</td><td>25</td><td>0</td><td>25</td><td>160</td><td>22314</td></tr><tr><td>NT-4</td><td>60</td><td>40</td><td>0</td><td>40</td><td>128</td><td>19170</td></tr><tr><td>PARC</td><td>4</td><td>25</td><td>70</td><td>96</td><td>12</td><td>1870</td></tr><tr><td>Rantes</td><td>0</td><td>13</td><td>87</td><td>100</td><td>5</td><td>1302</td></tr><tr><td>SCF</td><td>29</td><td>71</td><td>0</td><td>71</td><td>69</td><td>20306</td></tr><tr><td>TARC</td><td>15</td><td>85</td><td>0</td><td>85</td><td>21</td><td>3134</td></tr><tr><td>TNF-R1</td><td>2</td><td>97</td><td>1</td><td>98</td><td>108</td><td>16285</td></tr><tr><td>TNF-a</td><td>71</td><td>29</td><td>0</td><td>29</td><td>56</td><td>6901</td></tr><tr><td>TNF-b</td><td>88</td><td>12</td><td>1</td><td>12</td><td>221</td><td>7617</td></tr><tr><td>VEGF</td><td>86</td><td>14</td><td>0</td><td>14</td><td>702</td><td>79564</td></tr><tr><td>sgp130</td><td>0</td><td>63</td><td>37</td><td>100</td><td>334</td><td>38573</td></tr></table> |
da8f2a49e758c9b02e97521ef9374f39c928506713244092a9c1e07ef898cb91.png | complex | <table><tr><td rowspan="3">Antimicrobial Agent</td><td colspan="2">Number (%) of <i>E. coli</i> Isolates</td><td rowspan="3">Test of Independence<i>p</i>-Value *</td></tr><tr><td>Adults</td><td>Young Children</td></tr><tr><td><i>n</i> = 296</td><td><i>n</i> = 86</td></tr><tr><td>Ampicillin</td><td>113 (38.2)</td><td>27 (31.4)</td><td>0.2506</td></tr><tr><td>Amoxicillin/Clavulanic acid</td><td>40 (13.5)</td><td>3 (3.5)</td><td>0.0096 *</td></tr><tr><td>Piperacillin</td><td>72 (24.3)</td><td>5 (5.8)</td><td>0.0002 *</td></tr><tr><td>Cephalothin</td><td>86 (29.1)</td><td>24 (27.9)</td><td>0.8362</td></tr><tr><td>Cefuroxime</td><td>20 (6.8)</td><td>3 (3.5)</td><td>0.3152</td></tr><tr><td>Cefotaxime</td><td>4 (1.4)</td><td>2 (2.7)</td><td>0.6206</td></tr><tr><td>Streptomycin</td><td>137 (46.3)</td><td>19 (22.1)</td><td><0.0001 *</td></tr><tr><td>Gentamicin</td><td>32 (10.8)</td><td>9 (10.5)</td><td>0.9273</td></tr><tr><td>Amikacin</td><td>30 (10.1)</td><td>7 (8.1)</td><td>0.5818</td></tr><tr><td>Tetracycline</td><td>63 (21.3)</td><td>17 (19.8)</td><td>0.7610</td></tr><tr><td>Doxycycline</td><td>46 (15.5)</td><td>11 (12.8)</td><td>0.5287</td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td>33 (11.1)</td><td>12 (14)</td><td>0.4776</td></tr><tr><td>Chloramphenicol</td><td>18 (6.1)</td><td>0</td><td>0.0171</td></tr><tr><td>Nalidixic acid</td><td>39 (13.2)</td><td>8 (9.3)</td><td>0.3358</td></tr><tr><td>Norfloxacin</td><td>8 (2.7)</td><td>2 (2.3)</td><td>1</td></tr><tr><td>Ciprofloxacin</td><td>8 (2.7)</td><td>2 (2.3)</td><td>1</td></tr><tr><td>Nitrofurantoin</td><td>12 (4.1)</td><td>3 (3.5)</td><td>1</td></tr><tr><td>Antimicrobial susceptibility characteristic</td><td></td><td></td><td></td></tr><tr><td>R</td><td>224 (75.7)</td><td>47 (54.7)</td><td>0.0002 *</td></tr><tr><td>MDR</td><td>90 (30.4)</td><td>12 (14)</td><td>0.0024 *</td></tr></table> |
761f9a5b08d3f31568538a3cfda133772b7e43c62a40e6a4fc26180e569d833d.png | complex | <table><tr><td>Qualitative Theme</td><td>Exemplar Quotation(s)</td></tr><tr><td colspan="2">Less Willing to Honestly Disclose SU/MH with PROs</td></tr><tr><td> Harder to disclose to computer</td><td>“It takes a lot for a person to express how they feel when you can be face to face with somebody. Emotionally and physically...being face to face with her ... It’s easier.” (Patient 20, Not Retained, MH only)</td></tr><tr><td> Fear of Provider Judgement</td><td>“Other patients see [will start] missing their appointments because they ashamed of what the doctor seen. Especially when you bring it to their attention...They’ll start shying away from the clinic” (Patient, Retained, SU only).</td></tr><tr><td colspan="2">More Willing to Honestly Disclose SU/MH with PROs</td></tr><tr><td> Easier to disclose to computer</td><td>“That would give the doctor herself an extra little something that well, I can read this and maybe they don’t want to open to me, but they’ll open up to this. So I think that’d be real good.” (Patient 19, Retained, SU only)</td></tr></table> |
6275e20c9d358655d303db991c68302863937d1c43c25e8cc5539a5e4bf4f188.png | simple | <table><tr><td>Modification</td><td>Role</td><td>Species/System</td><td>Region/Residue(s) </td><td>Enzyme</td><td>Reference(s)</td></tr><tr><td>Ubiquitination</td><td>Target for proteasome dependent degradation</td><td>Human Mcm10(HeLa, U2OS)in vivo</td><td>440–525783–803843–875(regions that can mediate degradation)</td><td>Cul4-DDB1-VprBP</td><td>[93,95,97,98]</td></tr><tr><td>Ubiquitination</td><td>Functional regulation during S-phase</td><td>Yeast Mcm10(<i>Saccharomyces cerevisiae</i>)</td><td>K85, K122, K319, K372, K414, K436</td><td>Not identified</td><td>[67,100]</td></tr><tr><td>Phosphorylation</td><td>Unknown function</td><td>Human Mcm10 (HeLa)</td><td>T85, S93, S150, S155, A182, S203, S204, A210, S212, T217, R286, T296, S488, S548, S555, S559, S577, S593, Y641, S644, T663, S706, S824(* only sites identified in more than 2 datasets are listed)</td><td>Not identified, except T85 which is ATR or ATM dependent.</td><td>[93,101,102,103,104,105,106,107,108,109,110,111,112]</td></tr><tr><td>Phosphorylation</td><td>Replisome stability</td><td><i>Xenopus</i> extract</td><td>S154, S173, S206, S596, S630, S690, S693</td><td>S-CDK</td><td>[113]</td></tr><tr><td>Acetylation</td><td>Protein stability and DNA binding</td><td>Human Mcm10</td><td>K267, K312 *, K318, K390 *, K657, K664, K668, K674 *, K681 *, K682 *, K683 *, K685 *, K737 *, K739 *, K745 *, K761 *, K768 *, K783, K847 *, K849 *, K853, K868, K874</td><td>p300 (acetylase)SIRT1 * deacetylase)* indicates subset of SIRT1 target residues</td><td>[62]</td></tr></table> |
a52da057c6c05602a07657c68ceb310ca716e93737217240e8da3c31caed5322.png | simple | <table><tr><td></td><td>Group</td><td>n =</td><td>Mean</td><td>Std dev.</td><td>Difference in means MT-AR (95% CI)</td><td>p</td></tr><tr><td>VAS</td><td>AR</td><td>19</td><td>3.3</td><td>26.3</td><td>15.0 (-1.1,31.2)</td><td>.067</td></tr><tr><td></td><td>MT</td><td>20</td><td>18.3</td><td>23.5</td><td></td><td></td></tr><tr><td>RMQ</td><td>AR</td><td>19</td><td>0.6</td><td>3.2</td><td>3.6 (1.1,6.2)</td><td>.006</td></tr><tr><td></td><td>MT</td><td>20</td><td>4.2</td><td>4.5</td><td></td><td></td></tr><tr><td>PRI</td><td>AR</td><td>19</td><td>-0.1</td><td>7.2</td><td>7.1 (2.0,12.2)</td><td>.007</td></tr><tr><td></td><td>MT</td><td>20</td><td>7.0</td><td>8.5</td><td></td><td></td></tr></table> |
caa031c25086c8ad1572f36d39dba2efba58b74a2817f4b55c2a10d73d0283e0.png | simple | <table><tr><td>Risser’s stage</td><td>Original method</td><td>French method</td></tr><tr><td>Stage 0</td><td>Micro-ossification (2)<sup>1</sup> Gas shadow (1)<sup>2</sup></td><td>Micro-ossification (2)<sup>1</sup> Gas shadow (1)<sup>2</sup></td></tr><tr><td>Stage 1</td><td>Skip ossification (2)<sup>3</sup> Gas shadow (1)<sup>2</sup></td><td>Gas shadow (1)<sup>2</sup> Skip ossification (2)<sup>3</sup></td></tr><tr><td>Stage 2</td><td>Skip ossification (1)<sup>3</sup> Miscalculation of excursion (4)<sup>4</sup></td><td>Skip ossification (1)<sup>3</sup> Miscalculation of excursion (2)<sup>4</sup></td></tr><tr><td>Stage 3</td><td>Miscalculation of excursion (5)<sup>4</sup></td><td>Micro-fusion (4)<sup>5</sup></td></tr><tr><td>Stage 4</td><td>Miscalculation of excursion (1)<sup>4</sup> Micro-fusion (3)<sup>5</sup></td><td>Skip ossification (2)<sup>3</sup> Pseudo-fusion (10)<sup>6</sup>Micro-fusion (4)<sup>5</sup></td></tr><tr><td>Stage 5</td><td>Skip ossification (2)<sup>3</sup> Pseudo-fusion (14)<sup>6</sup></td><td></td></tr></table> |
fb55a2347e03c80c40e81377863ab1465a7ac899dcad76e6119c132947952e82.png | complex | <table><tr><td> </td><td colspan="2">Skin to calyx distance</td><td> </td></tr><tr><td> </td><td colspan="3"></td></tr><tr><td> </td><td>≤75mm</td><td>>75mm</td><td>P value</td></tr><tr><td>Number</td><td>140</td><td>130</td><td> </td></tr><tr><td>Gender</td><td> </td><td> </td><td>0.823</td></tr><tr><td>Male</td><td>88</td><td>80</td><td> </td></tr><tr><td>Female</td><td>52</td><td>50</td><td> </td></tr><tr><td>Mean age (years)</td><td>43.09±12.5</td><td>45.4±12.4</td><td>0.129</td></tr><tr><td>Mean body mass index (kg/m<sup>2</sup>)</td><td>25.7±3.5</td><td>26.6±5.3</td><td>0.090</td></tr><tr><td>Mean stone size (mm)</td><td>21.7±5.8</td><td>22.8±6.0</td><td>0.143</td></tr><tr><td>Stone location</td><td> </td><td> </td><td>0.077</td></tr><tr><td>Complex stone</td><td>60</td><td>57</td><td> </td></tr><tr><td>Pelvis</td><td>31</td><td>34</td><td> </td></tr><tr><td>Lower</td><td>40</td><td>30</td><td> </td></tr><tr><td>Middle</td><td>8</td><td>6</td><td> </td></tr><tr><td>Upper</td><td>1</td><td>3</td><td> </td></tr><tr><td>Operation side</td><td> </td><td> </td><td>0.745</td></tr><tr><td>Left</td><td>76</td><td>68</td><td> </td></tr><tr><td>Right</td><td>64</td><td>62</td><td> </td></tr><tr><td>Degree of hydronephrosis</td><td> </td><td> </td><td>0.682</td></tr><tr><td>0</td><td>6</td><td>4</td><td> </td></tr><tr><td>1</td><td>72</td><td>66</td><td> </td></tr><tr><td>2</td><td>54</td><td>54</td><td> </td></tr><tr><td>3</td><td>6</td><td>6</td><td> </td></tr><tr><td>4</td><td>2</td><td>0</td><td> </td></tr><tr><td>Previous renal stone treatment</td><td> </td><td> </td><td>0.853</td></tr><tr><td>SWL</td><td>22</td><td>21</td><td> </td></tr><tr><td>PNL</td><td>14</td><td>17</td><td> </td></tr><tr><td>Open renal stone surgery</td><td>11</td><td>13</td><td> </td></tr></table> |
1f8c544e18392812f59a419bc21d075c93a6a927d6d9cd26730348a2fa3230b9.png | complex | <table><tr><td>Test set</td><td colspan="3">Our representation</td><td colspan="3">Shen's representation</td></tr><tr><td></td><td>SN (%)</td><td>SP (%)</td><td>AC (%)</td><td>SN (%)</td><td>SP (%)</td><td>AC (%)</td></tr><tr><td>1</td><td>86.5</td><td>88.5</td><td>87.5</td><td>69.2</td><td>84.6</td><td>76.9</td></tr><tr><td>2</td><td>73.1</td><td>88.5</td><td>80.8</td><td>69.2</td><td>84.6</td><td>76.9</td></tr><tr><td>3</td><td>76.9</td><td>86.5</td><td>81.7</td><td>78.8</td><td>82.7</td><td>80.8</td></tr><tr><td>Average</td><td>78.8</td><td>87.8</td><td>83.3</td><td>72.4</td><td>83.9</td><td>78.2</td></tr></table> |
74df669bea2b8f5907be8c3a4705cf86835e6d7d5cd39c7f4e2ccfd39c9477c0.png | simple | <table><tr><td>Characteristic</td><td>Improvisation</td><td>Composition</td></tr><tr><td>Context</td><td>Public or private</td><td>Private</td></tr><tr><td>Individual/group</td><td>Individual or group</td><td>Individual or group (less frequent)</td></tr><tr><td>Development</td><td>Continuous, linear, real-time act, extemporaneous creation</td><td>Continuous or discontinuous act, mediated creation</td></tr><tr><td>Experimentation</td><td>Extemporaneous experimentation; it can provide suggestions to composition</td><td>Reasoned experimentation</td></tr><tr><td>Abilities</td><td>Performing and compositional</td><td>Compositional</td></tr><tr><td>Processes</td><td>Anticipation, use of repertoire, emotive communication, feedback, and flow</td><td>Planning, translating from the sound to graph, idea generation, organization and construction, revision</td></tr><tr><td>Reversibility</td><td>Irreversible action, it cannot be changed</td><td>Reversible action, it can be changed until the final draft</td></tr><tr><td>Revision</td><td>It cannot be reviewed, but only adjusted in real-time during the performance with the feedback</td><td>It can be reviewed and improved</td></tr><tr><td>Control</td><td>Control of individual variables but not of group variables</td><td>Overall control of the score and of the complexity of the compositional process</td></tr><tr><td>Feedback</td><td>Real-time feedback</td><td>Feedback without real-time pressure</td></tr><tr><td>Process dynamics</td><td>Interactive process. It has an adaptable nature, it allows you to answer to context variables, it can be adjusted instantly. Challenge between performers, taking risks</td><td>Fix product. The composition can be interpreted but it is not possible to change the notes of the score</td></tr><tr><td>Communication</td><td>The author has a direct communication with the audience. It is more authentic and real than composition</td><td>The author has a communication with the audience mediated by the performer(s) who interprets his/her ideas</td></tr></table> |
6ce75f347b8ae64b60da97d0e704132427cb57a5aac66fe4d1c3577d01810846.png | simple | <table><tr><td>Comorbidities and outcomes</td><td>Estimate (mean or proportion)</td><td>95% CI</td></tr><tr><td>Number of comorbidities</td><td>7.54</td><td>(7.53-7.55)</td></tr><tr><td>Charlson comorbidity category</td><td> </td><td> </td></tr><tr><td> Low (1–2)</td><td>0.29%</td><td>(0.26%-0.31%)</td></tr><tr><td> Medium (3–4)</td><td>17.29%</td><td>(17.12%-17.46%)</td></tr><tr><td> High (5+)</td><td>82.42%</td><td>(82.25%-82.60%)</td></tr><tr><td>Inpatient death</td><td>3.15%</td><td>(3.08%-3.23%)</td></tr><tr><td>Inpatient length of stay (days)</td><td>5.22</td><td>(5.20-5.25)</td></tr><tr><td>Inpatient cost (2009 $US)</td><td>$11,313.28</td><td>($11,233.77-$11,329.80)</td></tr></table> |
62eb6c6bf729213ab1c2607944837c79cb679ff48f901da53634655fbcd78230.png | simple | <table><tr><td>Population</td><td>L</td><td><i>h</i></td><td><i>π</i></td><td><i>K</i></td><td><i>Ho</i></td><td><i>He</i></td><td><i>A</i><sub><i>R</i></sub></td><td><i>Fis</i></td><td>M-<i>He</i></td><td>M-<i>Rs</i></td></tr><tr><td>JL</td><td>12</td><td>0.800</td><td>0.07688</td><td>20.7564</td><td>0.600</td><td>0.780</td><td>10.275</td><td>0.255</td><td>0.73</td><td>6.27</td></tr><tr><td>HY</td><td>15</td><td>0.891</td><td>0.09296</td><td>25.1000</td><td>0.607</td><td>0.875</td><td>11.938</td><td>0.323</td><td>0.72</td><td>6.40</td></tr><tr><td>DB</td><td>8</td><td>0.862</td><td>0.08600</td><td>23.2196</td><td>0.786</td><td>0.832</td><td>8.000</td><td>0.092</td><td>0.68</td><td>5.68</td></tr><tr><td>XJ</td><td>10</td><td>0.807</td><td>0.10219</td><td>27.5919</td><td>0.741</td><td>0.792</td><td>8.262</td><td>0.084</td><td>0.70</td><td>6.20</td></tr><tr><td>HS</td><td>7</td><td>0.718</td><td>0.08387</td><td>22.6441</td><td>0.833</td><td>0.706</td><td>5.733</td><td>−0.164</td><td>0.67</td><td>5.27</td></tr></table> |
a87362be639f1a115e13667d03515ac4bedbdd37db96b60b2006652ada9bdd7b.png | complex | <table><tr><td rowspan="2">Conditions</td><td>In-the-bag dislocation</td><td>Out-of-the-bag dislocation</td><td>Overall</td></tr><tr><td>Group (<i>n</i> = 209)</td><td>Group (<i>n</i> = 21)</td><td>(<i>n</i> = 230)</td></tr><tr><td>Pseudoexfoliation</td><td>90 (43.1 %)</td><td>1 (4.8 %)</td><td>91 (39.6 %)</td></tr><tr><td>Eye rubbing or tapping*</td><td>30 (14.4 %)</td><td>4 (19.0 %)</td><td>34 (14.8 %)</td></tr><tr><td>Atopic dermatitis</td><td>16 (7.7 %)</td><td>2 (9.5 %)</td><td>18 (7.8 %)</td></tr><tr><td>Long axial length</td><td>24 (11.5 %)</td><td>2 (9.5 %)</td><td>26 (11.3 %)</td></tr><tr><td>Postvitrectomy</td><td>22 (10.5 %)</td><td>2 (9.5 %)</td><td>24 (10.4 %)</td></tr><tr><td>Postglaucoma surgery</td><td>6 (2.9 %)</td><td>0 (0.0 %)</td><td>6 (2.6 %)</td></tr><tr><td>Postkeratoplasty</td><td>2 (1.0 %)</td><td>0 (0.0 %)</td><td>2 (0.9 %)</td></tr><tr><td>Operative complications†</td><td>16 (7.7 %)</td><td>5 (23.8 %)</td><td>21 (9.1 %)</td></tr><tr><td>Secondary implantation‡</td><td>0 (0.0 %)</td><td>3 (14.3 %)</td><td>3 (1.3 %)</td></tr><tr><td>Retinitis pigmentosa</td><td>6 (2.9 %)</td><td>2 (9.5 %)</td><td>8 (3.5 %)</td></tr><tr><td>Primary angle closure</td><td>2 (1.0 %)</td><td>0 (0.0 %)</td><td>2 (0.9 %)</td></tr><tr><td>Chronic uveitis</td><td>2 (1.0 %)</td><td>0 (0.0 %)</td><td>2 (0.9 %)</td></tr><tr><td>Unidentifiable</td><td>33 (15.8 %)</td><td>3 (14.3 %)</td><td>36 (15.7 %)</td></tr></table> |
409a77416099dddec2900625aaf875bdf6bca5b1d22b806ab2a5acaede02ce0e.png | complex | <table><tr><td>Strains and conditions</td><td>Throughput (Mbp)</td><td colspan="2">Absolute counts</td><td colspan="2">Ratios</td></tr><tr><td> </td><td> </td><td>Reads aligned on reference genome</td><td>Uniquely aligned reads</td><td>Ratio considering DB110 HP as reference (all reads)</td><td>Ratio considering DB110 HP as reference (unique reads)</td></tr><tr><td>DB110 28 MPa (DB110 HP)</td><td>582</td><td>16.621.219</td><td>5.836.186</td><td>1.00</td><td>1.00</td></tr><tr><td>DB110 0.1 MPa (DB110 LP)</td><td>584</td><td>16.690.818</td><td>3.050.616</td><td>1.00</td><td>0.52</td></tr><tr><td>TW30 28 MPa (TW30 HP)</td><td>611</td><td>17.466.471</td><td>5.692.495</td><td>1.05</td><td>0.97</td></tr><tr><td>TW30 0.1 MPa (TW30 LP)</td><td>479</td><td>13.699.146</td><td>4.517.864</td><td>0.824</td><td>0.77</td></tr></table> |
14711257dfe4fe0f8925f1995031c7150aa21fe0124afdbfd3e3b092b3a41146.png | simple | <table><tr><td>Months</td><td>2 (<i>n</i> = 7)</td><td>8 (<i>n</i> = 9)</td><td>15 (<i>n</i> = 9)</td><td>24 (<i>n</i> = 9)</td></tr><tr><td>Blood Na ± mEq/L</td><td>141.31 ± 1.18</td><td>145.22 ± 1.56</td><td>145.81 ± 2.73</td><td>147.20 ± 1.22*</td></tr><tr><td>Blood K ± mEq/L</td><td>4.22 ± 0.13</td><td>5.46 ± 0.37*</td><td>5.42 ± 0.29*</td><td>5.45 ± 0.26*</td></tr><tr><td>UNaV <i>μ</i>Eq/min</td><td>0.56 ± 0.13</td><td>0.71 ± 0.06*</td><td>0.75 ± 0.05*</td><td>1.49 ± 0.14*</td></tr><tr><td>UKV <i>μ</i>Eq/min</td><td>1.31 ± 0.11</td><td>1.68 ± 0.15</td><td>2.00 ± 0.31*</td><td>3.03 ± 0.02*</td></tr><tr><td>Blood Aldosterone ng%</td><td>23.6 ± 0.82</td><td>13.2 ± 1.63*</td><td>15.7 ± 1.43*</td><td>13.7 ± 1.63*</td></tr></table> |
8617551206b498d990ff784a944c89f67af738bfd1811499426df6a6179c35a5.png | complex | <table><tr><td>Cost category</td><td>Cost (USD)</td><td>Percentage</td></tr><tr><td colspan="3"><i>Project costs of program implementation:</i></td></tr><tr><td> Support structure</td><td>57,794</td><td>14.2</td></tr><tr><td> Salary</td><td>196,839</td><td>48.3</td></tr><tr><td> Medicine</td><td>144,020</td><td>35.3</td></tr><tr><td> Supplies</td><td>9,301</td><td>2.3</td></tr><tr><td> Total financial cost</td><td>407,954</td><td>100.0</td></tr><tr><td colspan="3"><i>Estimated unit costs of program implementation:</i></td></tr><tr><td> Unit annual cost per <i>WAJA</i></td><td>3,610</td><td></td></tr><tr><td> Per capita cost</td><td>1.16</td><td></td></tr></table> |
289fca1fa8dffd831d80cf2a4f4a6fbda936bb7cd326d92f3d2598e42c607b6d.png | complex | <table><tr><td>Parameters</td><td>Definitions</td></tr><tr><td>Patient characteristics</td><td>Age, weight, height, body mass index (BMI), medical insurance status and performance status</td></tr><tr><td>Hospitalisation</td><td>LOS (length of hospitalisation post-operation), the procedure performed, diagnosis, operating time, name of surgery, intra-operative estimated blood loss</td></tr><tr><td>Post-operation</td><td>Time to full tolerance of free fluids (days), time to full tolerance of solid food (days), time to drain removal (days) hospitalisation expenses</td></tr><tr><td colspan="2">Complications</td></tr><tr><td>Infection</td><td>Wound infection, lung infection, intraperitoneal infection, operation space infection (fever, mild abdominal pain without radiographic abnormalities)</td></tr><tr><td>Post-operative nausea and vomiting (PONV)</td><td>It was recognised that nausea and vomiting are common side effects of surgical recovery</td></tr><tr><td>Ileus</td><td>Is a disruption of the normal propulsive ability of the gastrointestinal tract</td></tr><tr><td>Post-operative haemorrhage</td><td>Evidence of blood loss from drains or based on ultrasonography</td></tr><tr><td>Post-operative thrombosis</td><td>Evidence of blood thrombosis based on ultrasonography</td></tr><tr><td>APACHE II score</td><td>Acute Physiology and Chronic Health Evaluation II</td></tr></table> |
b23591e3870c042b961c95b8095022e368f2ca449aa0b85c96ad0e82411cc0ad.png | complex | <table><tr><td>Risk-factors</td><td>Level</td><td>Categorization</td></tr><tr><td>Herd<sup>1</sup></td><td>1,2,3,4</td><td> </td></tr><tr><td colspan="3">Sow-related factors</td></tr><tr><td rowspan="2">Parity</td><td>Young</td><td>1st parity</td></tr><tr><td>Mature</td><td>2nd-7th parity</td></tr><tr><td rowspan="2">Litter size</td><td>Large<sup>2</sup></td><td>Gilts: >15 piglets, Sows: >18 piglets</td></tr><tr><td>Small</td><td>Gilts: <16 piglets, Sows: < 19 piglets</td></tr><tr><td rowspan="2">Stillborn</td><td>Many</td><td>>1 piglet</td></tr><tr><td>Few</td><td>0-1 piglets</td></tr><tr><td rowspan="2">Clinical disease</td><td>Yes</td><td>Mastitis and/or temp > 39.5°C and/or leg problems and/or vulva discharge<sup>3</sup></td></tr><tr><td>No</td><td>None of the above</td></tr><tr><td colspan="3">Piglet-related factors<sup>4</sup></td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td> </td></tr><tr><td>Female</td><td> </td></tr><tr><td>Birth weight</td><td>Continuous scale</td><td> </td></tr><tr><td rowspan="2">Faecal consistency</td><td>Liquid</td><td>Watery or liquid consistency of rectal contents</td></tr><tr><td>Normal</td><td>Creamy, firm or solid consistency of rectal contents and if no faeces on swab</td></tr><tr><td rowspan="2">Flanks</td><td>Hollow</td><td>Area behind ribs turned inwards</td></tr><tr><td>Normal</td><td>Area behind ribs followed the line of the ribs</td></tr><tr><td rowspan="2">Hair coat</td><td>Rough</td><td>Hair coat appeared dull</td></tr><tr><td>Normal</td><td>Hair coat did not appear dull</td></tr></table> |
7b63e093ba31d8f2a1b8f03d745f2b4ddb17e01f356c4af9c5bf1b0b5d0151e2.png | simple | <table><tr><td>Site of metastases</td><td>PTC-GD</td><td>Euthyroid</td></tr><tr><td>Bone</td><td>2 (6.8%)</td><td>1 (0.4%)</td></tr><tr><td>Lung</td><td>0</td><td>2 (0.8%)</td></tr><tr><td>Bone + lung</td><td>2 (6.8%)</td><td>4 (1.6%)</td></tr><tr><td>Local recurrence + lung</td><td>0</td><td>3 (1.3%)</td></tr><tr><td>Local recurrence + lung + bone</td><td>0</td><td>3 (1.3%)</td></tr><tr><td>Local recurrence</td><td>1 (3.4%)</td><td>4 (1.7%)</td></tr></table> |
127fa2e0480ac2258f7053b082ecbefb4e29d4d4b2054a5a542a1475b0f76c5e.png | complex | <table><tr><td>Parameter</td><td>Description</td><td>Baseline cohort (<i>n</i> = 43)</td><td>PD cohort (<i>n</i> = 40)</td></tr><tr><td>Age at sample draw</td><td>Median age (range)</td><td>72 (37–83)</td><td>63 (35–88)</td></tr><tr><td rowspan="4">Adjuvant endocrine therapy (%)</td><td>No</td><td>26 (60)</td><td>26 (65)</td></tr><tr><td>Yes, tamoxifen only</td><td>10 (23)</td><td>9 (23)</td></tr><tr><td>Yes, tamoxifen + AI</td><td>5 (12)</td><td>4 (10)</td></tr><tr><td>Yes, AI only</td><td>2 (5)</td><td>1 (2)</td></tr><tr><td rowspan="2">Adjuvant chemotherapy (%)</td><td>No</td><td>34 (79)</td><td>28 (70)</td></tr><tr><td>Yes</td><td>9 (21)</td><td>12 (30)</td></tr><tr><td>Neoadjuvant therapies (%)</td><td>No</td><td>43 (100)</td><td>40 (100)</td></tr><tr><td rowspan="4">Number of previous lines endocrine therapy lines for MBC (%)</td><td>0</td><td>43 (100)</td><td></td></tr><tr><td>1</td><td></td><td>22 (55)</td></tr><tr><td>2</td><td></td><td>12 (30)</td></tr><tr><td>≥3</td><td></td><td>6 (15)</td></tr><tr><td rowspan="3">Endocrine therapy after start (BL cohort) or before PD (PD cohort) (%)</td><td>AI</td><td>30 (70)</td><td>25 (63)</td></tr><tr><td>Tamoxifen</td><td>13 (30)</td><td>7 (17)</td></tr><tr><td>Fulvestrant</td><td></td><td>8 (20)</td></tr><tr><td rowspan="3">Previous endocrine therapy lines for MBC (in case of inclusion at PD on ≥second‐line endocrine therapy) (%)</td><td>Yes, AI only</td><td></td><td>9 (23)</td></tr><tr><td>Yes, AI + tamoxifen</td><td></td><td>6 (15)</td></tr><tr><td>Yes, tamoxifen only</td><td></td><td>3 (7)</td></tr><tr><td>Progression on the current line (%)</td><td>Yes</td><td>35 (81)</td><td>40 (100)</td></tr><tr><td>CTC count</td><td>Median count (range)</td><td>81 (6–32492)</td><td>21 (5–2837)</td></tr></table> |
4745f4a86fa6e0cd501481113d03d78e21bd233abcab0c07a897b7324d8cc1f6.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="3">Cycling (%<i>W</i><sub>max</sub>) (<i>n</i> = 22)</td><td colspan="3">Knee extension (%MVC) (<i>n</i> = 23)</td></tr><tr><td>Baseline</td><td>30%</td><td>60%</td><td>Baseline</td><td>40%</td><td>75%</td></tr><tr><td colspan="7">Systole</td></tr><tr><td> Apical rot. (°)</td><td>9.40 ± 3.02</td><td>14.29 ± 4.20†</td><td>15.85 ± 5.04†</td><td>9.22 (5.55)</td><td>11.53 (6.30)*</td><td>13.58 (7.11)*</td></tr><tr><td> Basal rot. (°)</td><td>−4.32 ± 2.85</td><td>−6.40 ± 2.77*</td><td>−6.90 ± 2.57†</td><td>−4.56 ± 2.68</td><td>−3.26 ± 2.32</td><td>−4.73 ± 3.06</td></tr><tr><td> Twist (°)</td><td>13.21 ± 4.63</td><td>20.04 ± 4.76†</td><td>22.50 ± 4.93†</td><td>13.40 ± 4.80</td><td>14.72 ± 4.38</td><td>16.77 ± 5.54</td></tr><tr><td> Apical rot. velocity (° s<sup>−1</sup>)</td><td>62.12 (30.77)</td><td>123.32 (53.39) †</td><td>182.55 (42.82)†‡</td><td>59.65 (31.23)</td><td>100.95 (48.71)†</td><td>105.09 (70.98)†</td></tr><tr><td> Basal rot. velocity (° s<sup>−1</sup>)</td><td>−46.18 ± 15.28</td><td>−79.83 ± 25.51†</td><td>−114.63 ± 30.21†‡</td><td>−46.42 ± 14.95</td><td>−55.13 ± 15.34</td><td>−64.68 ± 19.84†</td></tr><tr><td> Twisting velocity (° s<sup>−1</sup>)</td><td>88.21 ± 20.51</td><td>145.11 ± 27.08†</td><td>209.05 ± 34.56†‡</td><td>89.15 ± 21.77</td><td>106.66 ± 21.00*</td><td>124.32 ± 34.89†**</td></tr><tr><td colspan="7">Diastole</td></tr><tr><td> Apical rot. velocity (° s<sup>−1</sup>)</td><td>−63.59 ± 17.05</td><td>−146.60 ± 31.52†</td><td>−204.35 ± 68.77†‡</td><td>−63.21 (25.81)</td><td>−80.15 (47.50)*</td><td>−119.03 (66.78)†‡</td></tr><tr><td> Basal rot. velocity (° s<sup>−1</sup>)</td><td>41.47 (25.94)</td><td>73.17 (48.76)†</td><td>109.41 (53.36)†‡</td><td>42.37 (26.22)</td><td>46.17 (16.68)</td><td>62.72 (28.00)</td></tr><tr><td> Untwisting velocity (° s<sup>−1</sup>)</td><td>−93.90 (29.62)</td><td>−193.19 (64.32)†</td><td>−267.31 (104.30)†‡</td><td>−90.60 (27.19)</td><td>−98.44 (43.54)</td><td>−138.42 (73.29)†‡</td></tr><tr><td> Time-to-peak (ms)</td><td>59.50 (28.50)</td><td>57.50 (27.00)</td><td>53.50 (28.00)</td><td>62.00 (31.00)</td><td>99.00 (64.00)</td><td>75.00 (75.00)</td></tr><tr><td> PUV % of diastole</td><td>7.00 (4.31)</td><td>15.45 (10.12)†</td><td>21.78 (12.53)†‡</td><td>8.33 (4.66)</td><td>19.11 (19.56)†</td><td>20.33 (30.11)†</td></tr></table> |
fe4c5dc1a3be5abf90c6b7c8e3b0a892b6a5bbb4d80d9824a091f7bd22fc453c.png | complex | <table><tr><td></td><td colspan="2">Walk Well</td><td colspan="2">Control</td><td colspan="3">Main between group comparison</td></tr><tr><td>Outcomes</td><td>N</td><td>Mean (SD)</td><td>N</td><td>Mean (SD)</td><td>Mean difference at 12-weeks (95 % CI)<sup>a</sup></td><td>p</td><td>ICC</td></tr><tr><td>Primary outcome</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Step count per day</td><td>42</td><td>4823 (2059)</td><td>40</td><td>4784 (2613)</td><td>69.5 (-1054 , 1193.3)</td><td>0.90</td><td>0.51</td></tr><tr><td>Secondary outcomes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Percentage time per day MVPA</td><td>42</td><td>3.0 (2.6)</td><td>40</td><td>3.1 (2.1)</td><td>0.3 (-0.7 , 1.3)</td><td>0.55</td><td>0.42</td></tr><tr><td>Percentage time per day sedentary</td><td>42</td><td>66.4 (10.0)</td><td>40</td><td>65.9 (12.0)</td><td>1.6 (-3.0 , 6.1)</td><td>0.49</td><td>0.22</td></tr><tr><td>Total MET minutes per week</td><td>37</td><td>1311.9 (1293.2)</td><td>37</td><td>1154.8 (1103.7)</td><td>56.0 (-428.8,540.9)</td><td>0.82</td><td>0.02</td></tr><tr><td>Body Mass Index (kg/m<sup>2</sup>)</td><td>43</td><td>32.1 (7.7)</td><td>43</td><td>32.9 (7.5)</td><td>−0.2 (-0.83,0.41)</td><td>0.49</td><td>0.00</td></tr><tr><td>Waist circumference (cm)</td><td>45</td><td>104.9 (16.9)</td><td>42</td><td>107.8 (17.8)</td><td>−1.6 (-3.93,0.64)</td><td>0.15</td><td>0.00</td></tr><tr><td>Subjective vitality (mean score)</td><td>39</td><td>14.6 (2.5)</td><td>35</td><td>14.3 (2.8)</td><td>0.3 (-0.85, 1.52)</td><td>0.57</td><td>0.00</td></tr><tr><td>Self-efficacy (mean score)</td><td>43</td><td>14.4 (3.0)</td><td>42</td><td>13.7 (3.7)</td><td>0.8 (-0.68, 2.22)</td><td>0.29</td><td>0.08</td></tr><tr><td>EQ-5D (mean health utility score)</td><td>44</td><td>0.8 (0.27)</td><td>43</td><td>0.7 (0.30)</td><td>0.0 (-0.09, 0.14)</td><td>0.70</td><td>0.00</td></tr></table> |
b07a4341b49d449e15d699439590adf40ad65a6b96de4de1f274122dbc13ceca.png | complex | <table><tr><td rowspan="2" colspan="2"></td><td colspan="3">Measures to stockpile</td><td rowspan="2">Total</td></tr><tr><td>Yes</td><td>No</td><td>Don't know</td></tr><tr><td rowspan="3">Hospital size</td><td><100</td><td>1 (12.5 %)</td><td>5 (62.5 %)</td><td>2 (25.0 %)</td><td>8 (100.0 %)</td></tr><tr><td>100-199</td><td>13 (72.2 %)</td><td>5 (27.8 %)</td><td>0 (0.0 %)</td><td>18 (100.0 %)</td></tr><tr><td>>199</td><td>9 (47.4 %)</td><td>9 (47.4 %)</td><td>1 (5.3 %)</td><td>19 (100.0 %)</td></tr><tr><td colspan="2">Total</td><td>23 (51.1 %)</td><td>19 (42.2 %)</td><td>3 (6.7 %)</td><td>45 (100.0 %)</td></tr></table> |
cf41c70b1789b61e3fd6914b4ade6a89b5aecef72d01413027ba29ce696e6980.png | complex | <table><tr><td rowspan="2"></td><td colspan="7">Area</td></tr><tr><td>Khagrachari</td><td>Cox’s Bazar</td><td>Bandarban</td><td>Rangamati</td><td>Netrokona</td><td>Total</td><td>Frequency</td></tr><tr><td>A (1,900 bp)</td><td>10</td><td>56</td><td>6</td><td>1</td><td>2</td><td>75</td><td>0.735</td></tr><tr><td>B (1,400 bp)</td><td>1</td><td>2</td><td>1</td><td>0</td><td>1</td><td>5</td><td>0.049</td></tr><tr><td>C (1,100 bp)</td><td>2</td><td>5</td><td>2</td><td>0</td><td>0</td><td>9</td><td>0.088</td></tr><tr><td>Mixed</td><td>2</td><td>10</td><td>0</td><td>0</td><td>1</td><td>13</td><td>0.127</td></tr></table> |
b423ef3f38e659b00e7e67c71229e8d8665b57eb84af31efb81b7b9755916f76.png | simple | <table><tr><td>No.</td><td>Abbreviated item</td><td>Factor 1</td><td>Factor 2</td><td>Factor 3</td><td>Factor 4</td><td><i>h</i><sup>2</sup></td></tr><tr><td>1</td><td>Abdominal bloating</td><td>0.78</td><td>0.22</td><td>0.10</td><td>0.14</td><td>0.69</td></tr><tr><td>2</td><td>Tenesmus</td><td>0.74</td><td>0.21</td><td>–0.00</td><td>0.12</td><td>0.61</td></tr><tr><td>3</td><td>Changed stool form</td><td>0.68</td><td>0.16</td><td>0.37</td><td>0.12</td><td>0.65</td></tr><tr><td>4</td><td>Changed stool frequency</td><td>0.69</td><td>0.03</td><td>0.39</td><td>0.15</td><td>0.65</td></tr><tr><td>5</td><td>Flatulence</td><td>0.73</td><td>0.22</td><td>0.16</td><td>0.22</td><td>0.66</td></tr><tr><td>6</td><td>Depression</td><td>0.24</td><td>0.77</td><td>0.12</td><td>0.27</td><td>0.73</td></tr><tr><td>7</td><td>Irritation</td><td>0.34</td><td>0.69</td><td>0.25</td><td>0.27</td><td>0.73</td></tr><tr><td>8</td><td>Angry</td><td>0.09</td><td>0.81</td><td>0.18</td><td>0.14</td><td>0.71</td></tr><tr><td>9</td><td>Nervousness</td><td>0.26</td><td>0.77</td><td>0.20</td><td>0.26</td><td>0.76</td></tr><tr><td>10</td><td>Finding a toilet</td><td>0.20</td><td>0.32</td><td>0.77</td><td>0.25</td><td>0.70</td></tr><tr><td>11</td><td>Holding back defecation</td><td>0.20</td><td>0.10</td><td>0.89</td><td>0.18</td><td>0.75</td></tr><tr><td>12</td><td>Unpredictability</td><td>0.21</td><td>0.26</td><td>0.80</td><td>0.21</td><td>0.84</td></tr><tr><td>13</td><td>Eating before going out</td><td>0.24</td><td>0.22</td><td>0.46</td><td>0.63</td><td>0.74</td></tr><tr><td>14</td><td>Consideration of foods</td><td>0.20</td><td>0.23</td><td>0.15</td><td>0.80</td><td>0.80</td></tr><tr><td>15</td><td>Favorite foods</td><td>0.16</td><td>0.21</td><td>0.09</td><td>0.87</td><td>0.86</td></tr><tr><td>16</td><td>Eating out</td><td>0.15</td><td>0.28</td><td>0.35</td><td>0.72</td><td>0.79</td></tr></table> |
e29d7d499456dd42d885c651be695baa727c68b2a368d718938cea8bef432986.png | simple | <table><tr><td></td><td>Mean</td><td>95% HPD</td><td>Posterior probability</td></tr><tr><td>PB2</td><td>August 2016</td><td>June – October 2016</td><td>0.9992</td></tr><tr><td>PB1</td><td>August 2016</td><td>July – October 2016</td><td>0.9993</td></tr><tr><td>PA</td><td>July 2016</td><td>May – October 2016</td><td>0.9995</td></tr><tr><td>HA</td><td>September 2016</td><td>July – October 2016</td><td>0.9997</td></tr><tr><td>NP</td><td>May 2016</td><td>October 2015 – October 2016</td><td>0.9997</td></tr><tr><td>NA</td><td>May 2016</td><td>June – October 2016</td><td>0.9689</td></tr><tr><td>M</td><td>August 2016</td><td>June – October 2016</td><td>0.4849</td></tr><tr><td>NS</td><td>September 2016</td><td>June – October 2016</td><td>0.9995</td></tr></table> |
a5691d0d73bcb2d28277371d3a0cf5c04a7b0960447791abb3b4a4c239560341.png | complex | <table><tr><td>Accession</td><td>Runs</td><td>0A</td><td>5A</td><td>10A</td><td>15A</td><td>20A</td><td>25A</td></tr><tr><td rowspan="7">SRX016359</td><td>SRR035678</td><td>4,373,013</td><td>4,373,128</td><td>4,373,220</td><td>4,373,338</td><td>4,374,306</td><td>4,840,614</td></tr><tr><td>SRR037439</td><td>2,028,240</td><td>2,028,376</td><td>2,028,503</td><td>2,028,622</td><td>2,028,900</td><td>2,069,175</td></tr><tr><td>SRR037440</td><td>4,385,598</td><td>4,385,761</td><td>4,385,880</td><td>4,386,034</td><td>4,386,793</td><td>4,794,397</td></tr><tr><td>SRR037441</td><td>2,161,858</td><td>2,162,012</td><td>2,162,156</td><td>2,162,303</td><td>2,162,646</td><td>2,205,932</td></tr><tr><td>SRR037442</td><td>4,840,368</td><td>4,840,534</td><td>4,840,669</td><td>4,840,802</td><td>4,841,777</td><td>5,319,375</td></tr><tr><td>SRR037443</td><td>2,043,229</td><td>2,043,370</td><td>2,043,531</td><td>2,043,665</td><td>2,043,916</td><td>2,070,547</td></tr><tr><td>SRR037444</td><td>1,939,846</td><td>1,939,970</td><td>1,940,096</td><td>1,940,204</td><td>1,940,597</td><td>1,988,929</td></tr></table> |
2d5ff5d449790ea738fbed9a1f3e3a6ed9c4d9fa2a59a3675461fe955218eb1b.png | simple | <table><tr><td>Conceptual definition </td><td>Operational definition </td></tr><tr><td>Prostate cancer knowledge—Participants’ understanding of CaP disease, prevention and detection. </td><td>Ten questions assessed participants’ prostate cancer knowledge using a True/False/Don’t Know scale. Each correct response had 1 point and incorrect response or ‘I don’t know’ response had 0 point. Higher score indicated high knowledge of prostate cancer information. </td></tr><tr><td>Prostate cancer early detection behaviour—CaP information seeking behaviour and CaP screening.</td><td>An index of Prostate Cancer Detection Behaviour was created by combining (sum) the responses of participants on prostate cancer screening by DRE in the last year (5 if Yes, and 0 if No); prostate cancer screening by PSA in the last year (5 if Yes, and 0 if No); prostate cancer information seeking behaviour (measured on a 5-point Strongly Agree–Strongly Disagree scale); prostate cancer discussion with a physician (measured on a 5-point Strongly Agree–Strongly Disagree scale); and paying attention to prostate cancer information (measured on a 5-point Strongly Agree–Strongly Disagree scale). The index score ranged from 0 to 25.</td></tr><tr><td>Prostate cancer screening intention—Participants’ expressed likelihood of screening for CaP in the future</td><td>Three questions were used to measure intention. For example, participants responded to the question: ‘Within the next year, I will get tested for prostate cancer with the Digital Rectal Examination (DRE)’ on a strongly disagree (1)–strongly agree (5) scale, with higher score indicating high intention.</td></tr><tr><td>Decisional conflict—Participants’ state of uncertainty about the course of action to take relative to CaP screening [34].</td><td>O’Connor’s scale [34] provided the items for decisional conflict. The scale used for this study assessed CaP screening uncertainty (3 items) and factors contributing to uncertainty (7 items) on a strongly disagree (1)–strongly agree (5) scale. An example of the screening uncertainty measure is ‘I’m unsure what to do when it comes to prostate cancer screening’. Lower score on this scale indicates high uncertainty. An example of the factors contributing to uncertainty measure is ‘I feel I know the risks and side effects of prostate cancer screening’. Higher score on this scale indicates greater number of factors contributing to uncertainty.</td></tr><tr><td>Satisfaction with the W.O.R.D video </td><td>Participants’ satisfaction was assessed by three questions. For example, participants responded to the statement, ‘The information I received from the Prostate Cancer Education video can best be described as’ using a Very Unsatisfactory (1)–Very Satisfactory scale (5) with higher score indicating high satisfaction. </td></tr><tr><td>Quality of the W.O.R.D video </td><td>Participants’ perceived quality was assessed by three questions. For example, participants responded to the statement, ‘The Prostate Cancer Education video can best be described as superior’ using a strongly disagree (1) strongly agree (5) scale, with higher score indicating high quality rating. </td></tr><tr><td>General assessment of the W.O.R.D video </td><td>Using a ‘Yes’, ‘No’ and ‘I can’t say’ scale, participants responded to ten questions focused on general assessment of the video. Examples were: Was the information provided by the video useful to you? Did you experience any difficulty with the video? In your opinion, would you say that the video is credible? </td></tr></table> |
b4c1925bf57d272f6fa2af977f6f06c677fec5eef2e169baa4ff7a9cae443ed7.png | simple | <table><tr><td>Input</td><td>Processing</td><td>Output</td></tr><tr><td>Alignment</td><td>Export to a different format</td><td>Alignment</td></tr><tr><td>Alignment</td><td>Remove sequences >80 % identical and columns with conservation <0.9</td><td>Alignment</td></tr><tr><td>Alignment</td><td>Construct neighbour-joining tree using Kimura distance correction</td><td>Distance matrix</td></tr><tr><td>Distance matrix</td><td>Reconstruct tree</td><td>Tree</td></tr><tr><td>Alignment</td><td>Apply bootstrap analysis</td><td>Bootstrap trees</td></tr></table> |
b33d9b98a18cdb40f54ab82765036c67be0a9f38e49d2e653e05b115c45fa585.png | complex | <table><tr><td>Source</td><td>Country</td><td>Filling (Years)</td><td>Remarks</td></tr><tr><td>R Franceys, et al. [15]</td><td>Various</td><td>15–25</td><td>Design recommendations for household properties</td></tr><tr><td>J Pickford [17]</td><td>East Africa</td><td>Over 30</td><td>Reported at a house hold level</td></tr><tr><td>P Morgan [53]</td><td>Zimbabwe</td><td>Over 30</td><td>Household latrine</td></tr><tr><td>DA Still and K Foxon [107]</td><td>South Africa</td><td>20</td><td>Design recommendation</td></tr><tr><td></td><td>South Africa</td><td>5–9</td><td>Empting time for most (85 %) pit latrines. Lower and higher filling rates were also noted</td></tr><tr><td>I Günther, et al. [56]</td><td>Uganda</td><td>5</td><td>Study in low income areas of Kampala, Uganda (Slums)</td></tr><tr><td>RN Kulabako, et al. [108]</td><td>Uganda</td><td><1</td><td>Low laying areas of peri-urban settlements in Kampala</td></tr><tr><td rowspan="3">K Adubofour, et al. [109]</td><td rowspan="3">Ghana (slums in Kusami metroplis)</td><td>4.2</td><td>Average filling time</td></tr><tr><td>>10</td><td>High income areas</td></tr><tr><td>0.25</td><td>Low income areas</td></tr><tr><td>E Appiah-Effah, et al. [57]</td><td>Ghana (Ashanti region)</td><td>6–10</td><td>Low income area in Ashanti region</td></tr></table> |
b7a8f81b17902be331edb003ecfff944a29417bb29091398c5d108dc159486fa.png | complex | <table><tr><td colspan="4">MONITORING LAYER</td><td rowspan="3">INFORMATION LAYER</td><td rowspan="3">INTERCHANGE LAYER</td></tr><tr><td colspan="2">Capture Subsystem</td><td rowspan="2">Analysis Subsystem</td><td rowspan="2"><i>Visualization & Control Subsystem</i></td></tr><tr><td>MDP</td><td>Probes</td></tr><tr><td><i>Communication events:</i></td><td rowspan="2">Composite probe: </td><td rowspan="3">Merging traces</td><td rowspan="6">Web-based visualization</td><td rowspan="6">XML records with TimeStamp, Metadata and Radio packet</td><td rowspan="3">Ethernet based platform</td></tr><tr><td><i>Transmission_Error</i></td></tr><tr><td><i>Routing_Error</i></td><td rowspan="2">Attached monitor node (Traps)</td></tr><tr><td><i>Transmission_success</i></td><td rowspan="3">Trace Analysis on the merged trace, based on several analysis tools</td><td rowspan="3">SQL database</td></tr><tr><td><i>Captured_Frame</i></td><td rowspan="2">Single probe: Sniffers</td></tr><tr><td><i>Mote_state</i></td></tr></table> |
947e0685766e54da74253ecaa62e1e612423291c9fb677aae327aa5a539e44ae.png | simple | <table><tr><td>Locus</td><td>Locus reference</td><td>Number of individuals genotyped in study population</td><td>Predicted allele size</td><td>Observed allele size range</td><td>Number of alleles obs.</td><td>H<sub>e</sub></td><td>H<sub>o</sub></td><td>Est. null allele freq. (CERVUS v3.0)</td><td>Mean estimated error rate (CERVUS v3.0)</td><td>Multiplex set</td></tr><tr><td>ZF01-020</td><td>This study</td><td>320</td><td>178</td><td>160-261</td><td>15</td><td>0.69</td><td>0.59</td><td>0.075</td><td>0.007</td><td>3</td></tr><tr><td>ZF01-025</td><td>This study</td><td>334</td><td>211</td><td>188-217</td><td>11</td><td>0.78</td><td>0.77</td><td>0.005</td><td>0</td><td>2, 3</td></tr><tr><td>TG01-040</td><td>This study</td><td>307</td><td>286</td><td>286-294</td><td>7</td><td>0.69</td><td>0.70</td><td>-0.011</td><td>0</td><td>2</td></tr><tr><td>ZF01-054<sup>a</sup></td><td>This study</td><td>308</td><td>185</td><td>157-188</td><td>13</td><td>0.89</td><td>0.75</td><td>0.083</td><td>0.002</td><td>2</td></tr><tr><td>ZF01-139<sup>b</sup></td><td>This study</td><td>330</td><td>188</td><td>156-209</td><td>4</td><td>0.53</td><td>0.55</td><td>-0.007</td><td>0.040</td><td>4</td></tr><tr><td>ZF01-136</td><td>This study</td><td>299</td><td>367</td><td>333-373</td><td>10</td><td>0.73</td><td>0.55</td><td>0.138<sup>$</sup></td><td>0</td><td>2</td></tr><tr><td>ZF01-170<sup>c</sup></td><td>[47]</td><td>21</td><td>316</td><td>257-305</td><td>9</td><td>0.83</td><td>0.86</td><td>-0.032</td><td>-</td><td>4</td></tr><tr><td>ZF01-161</td><td>This study</td><td>333</td><td>159</td><td>125-168</td><td>8</td><td>0.70</td><td>0.74</td><td>-0.036</td><td>0</td><td>4</td></tr><tr><td>ZF01-190</td><td>This study</td><td>329</td><td>342</td><td>308-366</td><td>12</td><td>0.83</td><td>0.87</td><td>-0.026</td><td>0</td><td>3</td></tr><tr><td>ZF01-196</td><td>This study</td><td>334</td><td>292</td><td>270-304</td><td>7</td><td>0.74</td><td>0.77</td><td>-0.014</td><td>0</td><td>2, 3, 4</td></tr><tr><td>Tgu12</td><td>This study</td><td>331</td><td>282</td><td>248-273</td><td>10</td><td>0.79</td><td>0.75</td><td>0.026</td><td>0.016</td><td>3</td></tr><tr><td>ZF01-180<sup>b</sup></td><td>[43]</td><td>331</td><td>213</td><td>166-218</td><td>8</td><td>0.76</td><td>0.66</td><td>0.071</td><td>0.060</td><td>4</td></tr><tr><td>ZF01-081<sup>b</sup></td><td>This study</td><td>337</td><td>233</td><td>130-154</td><td>5</td><td>0.55</td><td>0.51</td><td>0.031</td><td>0.077</td><td>4</td></tr><tr><td>ZF02-068</td><td>This study</td><td>292</td><td>185</td><td>121-152</td><td>7</td><td>0.70</td><td>0.50</td><td>0.157<sup>$</sup></td><td>0.010</td><td>2</td></tr><tr><td>ZF02-038<sup>b</sup></td><td>This study</td><td>301</td><td>233</td><td>211-245</td><td>11</td><td>0.77</td><td>0.66</td><td>0.074</td><td>0.085</td><td>2</td></tr><tr><td>TG02-078</td><td>[43]</td><td>314</td><td>309</td><td>308-321</td><td>6</td><td>0.73</td><td>0.76</td><td>-0.024</td><td>0</td><td>1</td></tr><tr><td>TG02-088</td><td>[43]</td><td>310</td><td>268</td><td>263-269</td><td>5</td><td>0.73</td><td>0.77</td><td>-0.034</td><td>0</td><td>1</td></tr><tr><td>Ase44</td><td>[64]</td><td>303</td><td>268</td><td>308-329</td><td>8</td><td>0.81</td><td>0.79</td><td>0.010</td><td>0.006</td><td>2</td></tr><tr><td>ZF02-128</td><td>This study</td><td>301</td><td>374</td><td>365-435</td><td>9</td><td>0.83</td><td>0.79</td><td>0.022</td><td>0.005</td><td>2</td></tr><tr><td>ZF02-129</td><td>This study</td><td>329</td><td>169</td><td>124-172</td><td>11</td><td>0.83</td><td>0.82</td><td>0.004</td><td>0.005</td><td>3</td></tr><tr><td>ZEST09-005</td><td>Dawson et al. unpublished</td><td>316</td><td>168</td><td>155-165</td><td>5</td><td>0.74</td><td>0.67</td><td>0.047</td><td>0</td><td>1</td></tr><tr><td>Smm4</td><td>[65]</td><td>313</td><td>332</td><td>332-341</td><td>6</td><td>0.57</td><td>0.50</td><td>0.049<sup>$</sup></td><td>0.018</td><td>1</td></tr><tr><td>Cpi7</td><td>[66]</td><td>308</td><td>128</td><td>119-131</td><td>5</td><td>0.54</td><td>0.55</td><td>-0.016</td><td>0</td><td>1</td></tr><tr><td>ZEST09-018</td><td>Dawson et al. unpublished</td><td>289</td><td>285</td><td>282-293</td><td>8</td><td>0.70</td><td>0.75</td><td>-0.039</td><td>0</td><td>1</td></tr><tr><td>ZEST09-021</td><td>Dawson et al. unpublished</td><td>311</td><td>119</td><td>114-121</td><td>5</td><td>0.47</td><td>0.41</td><td>0.096</td><td>0</td><td>1</td></tr><tr><td>ZEST09-025</td><td>Dawson et al. unpublished</td><td>281</td><td>167</td><td>164-170</td><td>6</td><td>0.71</td><td>0.69</td><td>0.014</td><td>0</td><td>1</td></tr></table> |
1e757b99bc576bccba701bc4b7b60ad7870998aefd8211419651bca55e965f9c.png | simple | <table><tr><td>Poroscientific Model 740</td><td>Relative uncertainty (<i>k</i> = 1)</td><td>Absolute uncertainty</td><td>Percent contribution</td><td>Comments</td></tr><tr><td>LP CFV stagnation pres., <i>P</i><sub>0</sub> = 570.03 kPa</td><td>(× 10<sup>−6</sup>)</td><td>(Pa)</td><td>(%)</td><td></td></tr><tr><td>Calibration transfer standard for static pres.</td><td>17</td><td>9.7</td><td>2.1</td><td>Traceable to NIST Pres. and Vacuum Group</td></tr><tr><td>Drift limit</td><td>60</td><td>34.2</td><td>25.6</td><td>< 0.01 % in 6 months, assume rect. distrib.</td></tr><tr><td>Residuals, hysteresis, thermal effects</td><td>100</td><td>57.0</td><td>71.3</td><td>From cal. records, experiments</td></tr><tr><td>Dynamic pres. Unc.</td><td>12</td><td>6.7</td><td>1</td><td>Est. based on unc. of 10 % u(M) and 5 %</td></tr><tr><td>RSS</td><td>118</td><td>67.5</td><td>100</td><td></td></tr></table> |
b0c0dbaf93d45e47df87cc302be9ffd013c966c41c7152f731735017fcf259b5.png | complex | <table><tr><td colspan="5">Quartiles of DDS</td></tr><tr><td></td><td>1st (n = 37)</td><td>2nd (n = 34)</td><td>3rd (n = 46)</td><td>4th (n = 43)</td></tr><tr><td>FSG (mg/dl)</td><td>93.73 ± 12.40</td><td>88.00 ± 12.11</td><td>87.83 ± 13.90</td><td>90.55 ± 16.51</td></tr><tr><td>TG (mg/dl)</td><td>200.47 ± 104.85 <sup>a</sup></td><td>197.87 ± 141.02</td><td>194.76 ± 119.80</td><td>168.50 ± 71.25</td></tr><tr><td>TC (mg/dl)</td><td>189.29 ± 52.61</td><td>191.61 ± 38.11</td><td>187.34 ± 33.62</td><td>191.17 ± 37.63</td></tr><tr><td>LDL (mg/dl)</td><td>122.23 ± 4.56</td><td>123.12 ± 34.65</td><td>122.56 ± 45.98</td><td>122.18 ± 54.65</td></tr><tr><td>HDL (mg/dl)</td><td>40.05 ± 11.05</td><td>40.85 ± 9.36</td><td>41.30 ± 9.22</td><td>42.32 ± 10.78</td></tr><tr><td>SBP (mmHg)</td><td>133.05 ± 9.70<sup>a</sup></td><td>132.08 ± 8.70</td><td>128.70 ± 8.56</td><td>128.69 ± 3.12</td></tr><tr><td>DBP (mmHg)</td><td>88.08 ± 5.07</td><td>87.74 ± 3.37</td><td>89.39 ± 6.65</td><td>87.62 ± 9.19</td></tr><tr><td>Adiponectin (ng/ml)</td><td>11.82 ± 4.35 <sup>a</sup></td><td>14.50 ± 4.12</td><td>14.27 ± 3.70</td><td>15.27 ± 5.72</td></tr></table> |
2280b4abc19b850f972dbf35776a5a6301c475463fb4ee40554d70d593ddf7e1.png | simple | <table><tr><td>Bacteria</td><td>Total (<i>N</i> = 221)</td></tr><tr><td>Gram-negative organisms</td><td> </td></tr><tr><td> <i>Klebsiella</i> species</td><td>83 (38%)</td></tr><tr><td> <i>Escherichia coli</i></td><td>72 (33%)</td></tr><tr><td> <i>Pseudomonas aeruginosa</i></td><td>10 (5%)</td></tr><tr><td> <i>Enterobacter</i> species</td><td>8 (4%)</td></tr><tr><td> <i>Proteus</i> species</td><td>3 (1%)</td></tr><tr><td> <i>Citrobacter</i> species</td><td>3 (1%)</td></tr><tr><td> <i>Serratia</i> species</td><td>1 (1%)</td></tr><tr><td> <i>Acinetobacter</i> species</td><td>1 (1%)</td></tr><tr><td>Gram-positive organisms</td><td> </td></tr><tr><td> <i>Enterococcus</i> species</td><td>18 (8%)</td></tr><tr><td> <i>Streptococcus</i> species</td><td>17 (8%)</td></tr><tr><td> <i>Staphylococcus</i> species</td><td>2 (1%)</td></tr><tr><td>Anaerobes</td><td> </td></tr><tr><td> <i>Bacteroides</i> species</td><td>3 (1%)</td></tr></table> |
bd45d7036ad6b91d2dd60f4eb9f1cfc430aa520cc59c71f6f3524b0cf9e71698.png | complex | <table><tr><td rowspan="2"><i>Level</i></td><td colspan="3"><i>2005–2007</i></td><td colspan="3"><i>2002–2004</i></td></tr><tr><td><i>Total deaths</i></td><td><i>HT deaths</i></td><td><i>%</i></td><td><i>Total deaths</i></td><td><i>HT deaths</i></td><td><i>%</i></td></tr><tr><td>Level 1</td><td>1429</td><td>162</td><td>11.3</td><td>1103</td><td>149</td><td>13.5</td></tr><tr><td>Level 2</td><td>1527</td><td>232</td><td>15.2</td><td>1241</td><td>234</td><td>18.9</td></tr><tr><td>Level 3</td><td>850</td><td>202</td><td>23.8</td><td>941</td><td>233</td><td>24.8</td></tr></table> |
a9dc2a53337ca3a6ef2bbd318f68a912dc72fd6e9a1111144c2fa36699d96534.png | complex | <table><tr><td></td><td colspan="2">APPLE Schools<sup>a</sup></td><td colspan="2">Alberta Schools<sup>b</sup></td><td colspan="2">Intervention Effect: Change in APPLE Schools over time relative to the coinciding change in Alberta schools (95% CI)<sup>b</sup></td></tr><tr><td>Fruits and vegetables consumption per day (β and 95% CI)</td><td>0.39</td><td>(0.00, 0.78)</td><td>-0.12</td><td>(-0.29, 0.06)</td><td>0.55</td><td>(-0.02, 1.13)</td></tr><tr><td>Dietary energy intake (kcal) per day (β and 95% CI)</td><td>-236.51</td><td>(-366.22, -106.81)</td><td>-25.89</td><td>(-78.34, 26.56)</td><td>-212.11</td><td>(-315.07, -109.16)</td></tr><tr><td>DQI score (β and 95% CI)</td><td>0.96</td><td>(-0.28, 2.19)</td><td>-0.23</td><td>(-0.77, 0.31)</td><td>1.14</td><td>(-0.55, 2.83)</td></tr><tr><td>PAQ-C score (β and 95% CI)</td><td>0.13</td><td>(0.03,0.23)</td><td>0.02</td><td>(-0.01, 0.06)</td><td>0.10</td><td>(0.01, 0.20)</td></tr><tr><td>Obesity (Odds Ratio and 95% CI)</td><td>0.84</td><td>(0.52, 1.36)</td><td>1.37</td><td>(1.11, 1.70)</td><td>0.61</td><td>(0.35, 1.06)</td></tr></table> |
60e36a943f255bfd49d184f04a8c5a7cfc8a3beac9d5aa300197bd6ef4ca3c59.png | simple | <table><tr><td>Sample<sup>a</sup></td><td>HW Category<sup>b</sup></td><td>Witness® HW</td><td>SNAP® RT</td><td>DiroChek®</td><td>Sample OD(+ control OD) Initial Test</td><td>Sample OD(+ control OD)Post-Heat Treatment</td></tr><tr><td>1</td><td>BL</td><td>+ (+)</td><td>− (vol.<sup>b</sup>)</td><td>+ (+)</td><td>0.038 (0.352)</td><td>0.049 (0.309)</td></tr><tr><td>23</td><td>BL</td><td>+ (+)</td><td>− (+)</td><td>+ (+)</td><td>0.013 (0.363)</td><td>0.070 (0.309)</td></tr><tr><td>26</td><td>BL</td><td>− (−)</td><td>− (−)</td><td>+ (−)</td><td>0.015 (0.363)</td><td>0.000 (0.309)</td></tr><tr><td>52</td><td>BL</td><td>+ (+)</td><td>− (+)</td><td>+ (+)</td><td>0.027 (0.470)</td><td>0.124 (0.309)</td></tr><tr><td>62</td><td>BL</td><td>+ (+)</td><td>− (+)</td><td>+ (+)</td><td>0.020 (0.470)</td><td>0.077 (0.309)</td></tr><tr><td>68</td><td>BL</td><td>− (+)</td><td>− (+)</td><td>+ (+)</td><td>0.019 (0.380)</td><td>0.050 (0.309)</td></tr><tr><td>92</td><td>Neg.</td><td>+ (−)</td><td>− (−)</td><td>− (−)</td><td>0.000 (0.380)</td><td>0.000 (0.309)</td></tr><tr><td>98</td><td>BL</td><td>+ (+)</td><td>− (+)</td><td>− (+)</td><td>0.004 (0.380)</td><td>0.025 (0.309)</td></tr><tr><td>116</td><td>BL</td><td>− (−)</td><td>+ (−)</td><td>− (−)</td><td>0.001 (0.337)</td><td>0.000 (0.309)</td></tr><tr><td>121</td><td>BL</td><td>+ (+)</td><td>− (vol.<sup>c</sup>)</td><td>− (+)</td><td>0.009 (0.337)</td><td>0.126 (0.309)</td></tr></table> |
50c577441c32571ccd8659a3051a541e0dcd78df3057d085d1e0dba54143aea1.png | simple | <table><tr><td>Subscale</td><td>Experimental group (<i>n</i> = 25)</td><td>Control group (<i>n</i> = 23)</td></tr><tr><td>Anxiety</td><td></td><td></td></tr><tr><td> Week 0</td><td>6.3 ± 3.2</td><td>6.5 ± 3.4</td></tr><tr><td> Week 4</td><td>4.1 ± 2.9<sup>∗#</sup></td><td>6.1 ± 3.2</td></tr><tr><td>Depression</td><td></td><td></td></tr><tr><td> Week 0</td><td>4.9 ± 3.8</td><td>4.8 ± 3.1</td></tr><tr><td> Week 4</td><td>3.1 ± 2.8<sup>∗∗##</sup></td><td>4.6 ± 2.9</td></tr><tr><td>Total</td><td></td><td></td></tr><tr><td> Week 0</td><td>10.9 ± 4.1</td><td>10.8 ± 3.9</td></tr><tr><td> Week 4</td><td>7.1 ± 3.1<sup>∗∗##</sup></td><td>9.8 ± 3.4</td></tr></table> |
0d6cecfb256115a408b5ba7000cfcdc422c95b55e2ebae43fc8ac4db9b425099.png | complex | <table><tr><td>Acceptance Number</td><td>Drug</td><td>Date</td><td>Company</td><td>Progress</td></tr><tr><td>JXSL1600007</td><td rowspan="3">Nivolumab</td><td>17 February 2016</td><td rowspan="3">Bristol-Myers Squibb</td><td rowspan="2">In Assessing</td></tr><tr><td>JXSL1500068</td><td>7 December 2015</td></tr><tr><td>JXSL1300032</td><td>20 May 2013</td><td>In Clinic</td></tr><tr><td>JXSL1600009</td><td rowspan="6">Pembrolizumab</td><td>29 February 2016</td><td rowspan="6">Merck</td><td rowspan="6">In Assessing</td></tr><tr><td>JXSL1600005</td><td>16 February 2016</td></tr><tr><td>JXSL1500074</td><td>31 December 2015</td></tr><tr><td>JXSL1500058</td><td>30 September 2015</td></tr><tr><td>JXSL1500040</td><td>28 July 2015</td></tr><tr><td>JXSL1500020</td><td>25 May 2015</td></tr><tr><td>CXSL1400138</td><td>JS001-PD-1</td><td>21 January 2015</td><td>ShangHai JunShi</td><td rowspan="2">In Clinic</td></tr><tr><td>CXSL1400153</td><td>SHR-1210</td><td>19 January 2015</td><td>ShangHai HengRui</td></tr><tr><td>CXSL1500096</td><td>BGB-317</td><td>11 December 2015</td><td>BeiGene</td><td rowspan="2">In Assessing</td></tr><tr><td>CXSL1600016</td><td>Genor PD-1 Antibody</td><td>7 April 2016</td><td>Genorbio</td></tr></table> |
bba5b52a46200a69ab634a211bdea601c5af91dee2c2576a793dd5098f9c8da3.png | simple | <table><tr><td>PDB code of the receptor</td><td>AutoDock binding energy (kcal/mol)</td><td>PDB code of the receptor</td><td>AutoDock binding energy (kcal/mol)</td></tr><tr><td>1A8G</td><td>-7.28</td><td>3EKX</td><td>-7.95</td></tr><tr><td>1A9M</td><td>-8.30</td><td>3EM3</td><td>-8.90</td></tr><tr><td>1AJV</td><td>-7.77</td><td>3MXD</td><td>-7.86</td></tr><tr><td>1AJX</td><td>-7.24</td><td>3MXE</td><td>-7.66</td></tr><tr><td>1BV9</td><td>-7.38</td><td>3NLS</td><td>-8.24</td></tr><tr><td>1BWA</td><td>-9.25</td><td>3O9F</td><td>-8.42</td></tr><tr><td>1BWB</td><td>-8.67</td><td>3O9H</td><td>-7.81</td></tr><tr><td>1CPI</td><td>-7.41</td><td>3O9I</td><td>-7.59</td></tr><tr><td>1DIF</td><td>-6.64</td><td>3O9G</td><td>-7.37</td></tr><tr><td>1GNO</td><td>-8.60</td><td>3SA3</td><td>-7.90</td></tr><tr><td>1HPV</td><td>-7.83</td><td>3SA4</td><td>-7.92</td></tr><tr><td>1IDB</td><td>-6.90</td><td>3SA5</td><td>-7.97</td></tr><tr><td>1MUI</td><td>-7.09</td><td>3SA6</td><td>-7.72</td></tr><tr><td>1T3R</td><td>-8.11</td><td>3SA7</td><td>-7.51</td></tr><tr><td>1T7J</td><td>-7.45</td><td>3SA8</td><td>-8.11</td></tr><tr><td>1XL2</td><td>-6.73</td><td>3SA9</td><td>-7.87</td></tr><tr><td>1XL5</td><td>-7.60</td><td>3SAA</td><td>-9.15</td></tr><tr><td>2I0A</td><td>-7.88</td><td>3SAB</td><td>-8.16</td></tr><tr><td>2I0D</td><td>-7.37</td><td>3SAC</td><td>-8.06</td></tr><tr><td>2PQZ</td><td>-7.32</td><td>4DJO</td><td>-7.85</td></tr><tr><td>2PSU</td><td>-7.66</td><td>4DJP</td><td>-7.46</td></tr><tr><td>2PSV</td><td>-8.12</td><td>4DJQ</td><td>-7.79</td></tr><tr><td>2Q5K</td><td>-8.00</td><td>4DJR</td><td>-7.67</td></tr><tr><td>2Q54</td><td>-8.19</td><td>4DQB</td><td>-7.85</td></tr><tr><td>2Q55</td><td>-7.33</td><td>3IXO</td><td>-4.94</td></tr><tr><td>3EKV</td><td>-8.10</td><td></td><td></td></tr></table> |
248f1d5e615d20a57417f48f0b5fd65c1b78fd35d7edf8590c17f448bce18325.png | simple | <table><tr><td>Inputs</td><td>Outputs</td></tr><tr><td>Solar irradiance spectra</td><td>Radiance spectrum</td></tr><tr><td>Gas absorption and scattering cross sections</td><td>Jacobians (partial derivatives of the radiance spectrum with respect to each of the state vector elements)</td></tr><tr><td>Atmospheric state</td><td>-</td></tr><tr><td>Surface state</td><td>-</td></tr><tr><td>Instrument line shape function</td><td>-</td></tr><tr><td>Aerosol optical properties</td><td>-</td></tr></table> |
dad3a4378100ea7955879023df8dcb145f42ccc069d32f50b593656096228ff5.png | complex | <table><tr><td>Imaging direction</td><td>Treatment</td><td>Sheep (<i>n</i> = 5)</td><td>Pigs (<i>n</i> = 3)</td></tr><tr><td rowspan="4">Dorsal/Ventral</td><td>Baseline</td><td>14</td><td>15</td></tr><tr><td>Hypertonic</td><td>1</td><td>7</td></tr><tr><td>Isotonic</td><td>0</td><td>6</td></tr><tr><td>Mannitol</td><td>0</td><td>3</td></tr><tr><td rowspan="4">Lateral</td><td>Baseline</td><td>14</td><td>10</td></tr><tr><td>Hypertonic</td><td>3</td><td>2</td></tr><tr><td>Isotonic</td><td>4</td><td>3</td></tr><tr><td>Mannitol</td><td>0</td><td>4</td></tr><tr><td rowspan="3">Other</td><td>Upside down</td><td>2</td><td>0</td></tr><tr><td>At 24 h</td><td>1</td><td>0</td></tr><tr><td>Lung</td><td>0</td><td>4</td></tr><tr><td></td><td></td><td>39</td><td>51</td></tr></table> |
af86ab6e2aa4481dddcdbbee3134cdcdb9fea0edc3d1146a3bebc69408a1c513.png | complex | <table><tr><td></td><td>Volume (ml)</td><td>Protein concentration (mg/l)</td><td>Specific activity (AU *10000/ml)</td><td>Total activity (AU*100000)</td><td>Recovery (%)</td></tr><tr><td>Culture supernatant</td><td>1000</td><td>1213.64 ± 42.68</td><td>15.36 ± 0.43</td><td>1536</td><td>100</td></tr><tr><td>Sephadex G-25</td><td>2600</td><td>357.31 ± 17.14</td><td>5.37 ± 0.08</td><td>1397</td><td>90.95</td></tr><tr><td colspan="6">SP FF</td></tr><tr><td>Sepharose</td><td>820</td><td>376.89 ± 15.83</td><td>15.52 ± 0.36</td><td>1273</td><td>82.93</td></tr></table> |
7c5fb81e4ae61c2dcfc88e16c106dc50a45832752dace0641383160a4c92f7d0.png | complex | <table><tr><td></td><td></td><td colspan="2">Median of Means (Range)</td><td></td><td></td></tr><tr><td>All available data</td><td>No. of comparisons</td><td>TEA group</td><td>GA group</td><td>WMD (95 % CI)</td><td><i>P</i> value</td></tr><tr><td colspan="6">During two-lung ventilation</td></tr><tr><td>PaO<sub>2</sub> (mmHg)</td><td>13</td><td>382.42(205.00 to 85.00)</td><td>377.92(191.0 to 453.00)</td><td>6.29 [0.04 to 12.17]</td><td>0.35</td></tr><tr><td>PaCO<sub>2</sub> (mmHg)</td><td>10</td><td>39.67 (32.50 to 37.6)</td><td>40.23 (35.60 to 37.40)</td><td>−0.21 [−1.11 to 0.68]</td><td>0.64</td></tr><tr><td>PvO<sub>2</sub> (mmHg)</td><td>7</td><td>51.50(48.00 to 55.0)</td><td>51.62(48.0 to 53.30)</td><td>0.27 [−1.51 to 2.06]</td><td>0.76</td></tr><tr><td>Qs/Qt (%)</td><td>13</td><td>14.80 (4.90 to 22.50)</td><td>15.50 (3.95 to 21.60)</td><td>0.02[−0.47 to 0.50]</td><td>0.95</td></tr><tr><td>SvO<sub>2</sub> (%)</td><td>4</td><td>85.37(83.30 to 87.10)</td><td>86.68(84.90 to 88.20)</td><td>−1.22[−2.36 to −0.07]</td><td>0.58</td></tr><tr><td>SaO<sub>2</sub> (%)</td><td>4</td><td>99.75(99.70 to 99.90)</td><td>99.45(99.00 to 99.90)</td><td>−0.06[−0.08 to −0.04]</td><td>0.30</td></tr><tr><td>PH</td><td>4</td><td>7.43 (7.42 to 7.43)</td><td>7.44 (7.43 to 7.44)</td><td>−0.01 [−0.02 to 0.00]</td><td>0.21</td></tr><tr><td>Paw (cmH<sub>2</sub>O)</td><td>4</td><td>18.63 (17.00 to 20.00)</td><td>19.03 (17.00 to 21.40)</td><td>−0.24 [−1.14 to 0.66]</td><td>0.60</td></tr><tr><td colspan="6">During one-lung ventilation within 30 min</td></tr><tr><td>PaO<sub>2</sub> (mmHg)</td><td>10</td><td>166.90(118.00 to 211.00)</td><td>171.2(122.00 to 201.00)</td><td>−16.52[−21.98 to -11.05]</td><td><0.01</td></tr><tr><td>PaCO<sub>2</sub> (mmHg)</td><td>10</td><td>37.12 (36.10 to 44.20)</td><td>36.85(34.20 to 42.20)</td><td>0.29 [−0.53 to 1.10]</td><td>0.49</td></tr><tr><td>PvO<sub>2</sub> (mmHg)</td><td>7</td><td>47.78(44.90 to 54.00)</td><td>46.14(44.50 to 51.00)</td><td>1.13 [−0.50 to 2.76]</td><td>0.17</td></tr><tr><td>Qs/Qt (%)</td><td>10</td><td>33.32 (27.30 to 39.50)</td><td>32.77 (26.70 to 40.60)</td><td>2.53 [1.35 to 3.72]</td><td><0.01</td></tr><tr><td>SvO<sub>2</sub> (%)</td><td>4</td><td>80.53(78.30 to 82.60)</td><td>81.58(78.40 to 84.20)</td><td>−1.13[−2.74 to 0.48]</td><td>0.17</td></tr><tr><td>SaO<sub>2</sub> (%)</td><td>4</td><td>97.98(96.80 to 99.30)</td><td>97.65(97.30 to 98.00)</td><td>0.74[0.33 to 1.15]</td><td><0.01</td></tr><tr><td>PH</td><td>4</td><td>7.43 (7.42 to 7.44)</td><td>7.44 (7.42 to 7.46)</td><td>−0.01 [−0.02 to 0.001]</td><td>0.41</td></tr><tr><td>Paw (cmH<sub>2</sub>O)</td><td>4</td><td>28.00 (23.00 to 32.50)</td><td>27.00 (24.00 to 30.90)</td><td>1.95 [1.61 to 2.28]</td><td><0.01</td></tr><tr><td colspan="6">One-lung ventilation more than 30 min</td></tr><tr><td>PaO<sub>2</sub> (mmHg)</td><td>11</td><td>162.27(117.00 to 203.00)</td><td>168.72(148.00 to 221.00)</td><td>−14.23[−20.81 to -7.65]</td><td><0.01</td></tr><tr><td>PaCO<sub>2</sub> (mmHg)</td><td>11</td><td>36.61 (33.90 to 44.60)</td><td>36.78 (35.00 to 44.20)</td><td>−0.22 [−0.96 to 0.53]</td><td>0.57</td></tr><tr><td>PvO<sub>2</sub> (mmHg)</td><td>6</td><td>44.70(42.60 to 46.10)</td><td>44.98(43.40 to 46.60)</td><td>−0.61[−2.23 to 1.02]</td><td>0.46</td></tr><tr><td>Qs/Qt (%)</td><td>12</td><td>34.40 (33.60 to 42.70)</td><td>32.67 (32.10 to 40.90)</td><td>2.77 [1.81 to 3.74]</td><td><0.01</td></tr><tr><td>SvO<sub>2</sub> (%)</td><td>6</td><td>79.33(77.40 to 81.10)</td><td>81.97(78.50 to 83.90)</td><td>−2.39[−3.73 to −0.99]</td><td><0.01</td></tr><tr><td>SaO<sub>2</sub> (%)</td><td>6</td><td>97.68(96.60 to 98.10)</td><td>98.20(97.20 to 99.00)</td><td>−0.63[−1.23 to −0.04]</td><td>0.04</td></tr><tr><td>PH</td><td>6</td><td>7.43 (7.43 to 7.44)</td><td>7.44 (7.41 to 7.46)</td><td>0.00 [−0.01 to 0.01]</td><td>0.50</td></tr><tr><td>Paw (cmH<sub>2</sub>O)</td><td>6</td><td>26.80 (24.00 to 32.50)</td><td>26.72 (24.00 to 31.40)</td><td>0.87 [0.54 to 1.20]</td><td><0.01</td></tr><tr><td colspan="6">Re-two ventilation</td></tr><tr><td>PaO<sub>2</sub> (mmHg)</td><td>7</td><td>322.28(173.00 to 482.00)</td><td>307.28(168.00 to 407.00)</td><td>11.54[−4.25 to 27.34]</td><td>0.15</td></tr><tr><td>PaCO<sub>2</sub> (mmHg)</td><td>3</td><td>37.8 (34.00 to 46.10)</td><td>35.6 (34.90 to 36.90)</td><td>−0.60 [−3.03 to 1.83]</td><td>0.63</td></tr><tr><td>PvO<sub>2</sub> (mmHg)</td><td>5</td><td>47.82(43.00 to 50.00)</td><td>48.68(46.20 to 51.00)</td><td>0.06[−2.24 to 2.36]</td><td>0.96</td></tr><tr><td>Qs/Qt (%)</td><td>6</td><td>18.55(15.30 to 24.50)</td><td>20.15(15.50 to 24.80)</td><td>−1.27 [−2.73 to 0.20]</td><td>0.09</td></tr><tr><td>SvO<sub>2</sub> (%)</td><td>2</td><td>81.90(81.50 to 82.30)</td><td>85.30(85.30 to 85.30)</td><td>−3.62[−6.28 to −0.95]</td><td>0.80</td></tr><tr><td>SaO<sub>2</sub> (%)</td><td>2</td><td>99.75(99.70 to 99.80)</td><td>99.00 (99.00 to 99.00)</td><td>0.75[0.52 to 0.98]</td><td>0.67</td></tr><tr><td>PH</td><td>2</td><td>7.42 (7.41 to 7.42)</td><td>7.42 (7.42 to 7.42)</td><td>0.00 [−0.03 to 0.02]</td><td>0.77</td></tr><tr><td>Paw (cmH<sub>2</sub>O)</td><td>2</td><td>19.00 (18.00 to 20.00)</td><td>18.00 (18.00 to 18.00)</td><td>0.95 [−0.81 to 2.71]</td><td>0.29</td></tr></table> |
1d3945a7bbdaab41c28c56e991c0f1d93f3ed8a38bae27bf9ee69f5519bcacba.png | complex | <table><tr><td>Quintiles of Dietary Intake</td><td>No. Cases</td><td>Person-Years</td><td>Multivariate Adjusted HR (95% CI) <sup>1</sup></td></tr><tr><td colspan="4">Total fiber (g/day)</td></tr><tr><td><10.3</td><td>420</td><td>302,828</td><td>1.00 (Reference)</td></tr><tr><td>10.3–13.6</td><td>426</td><td>312,546</td><td>1.00 (0.87, 1.15)</td></tr><tr><td>13.6–17.0</td><td>354</td><td>316,244</td><td>0.83 (0.71, 0.97)</td></tr><tr><td>17.0–21.5</td><td>372</td><td>318,893</td><td>0.87 (0.74, 1.03)</td></tr><tr><td>>21.5</td><td>380</td><td>318,844</td><td>0.90 (0.73, 1.10)</td></tr><tr><td><i>p-trend</i></td><td></td><td></td><td>0.09</td></tr><tr><td colspan="4">Soluble fiber (g/day)</td></tr><tr><td><2.8</td><td>408</td><td>304,051</td><td>1.00 (Reference)</td></tr><tr><td>2.8–3.7</td><td>409</td><td>312,599</td><td>0.97 (0.84, 1.12)</td></tr><tr><td>3.7–4.6</td><td>361</td><td>316,928</td><td>0.85 (0.73, 1.00)</td></tr><tr><td>4.6–5.8</td><td>410</td><td>318,628</td><td>0.96 (0.81, 1.13)</td></tr><tr><td>>5.8</td><td>364</td><td>317,148</td><td>0.84 (0.69, 1.03)</td></tr><tr><td><i>p-trend</i></td><td></td><td></td><td>0.14</td></tr><tr><td colspan="4">Insoluble fiber (g/day)</td></tr><tr><td><7.4</td><td>433</td><td>302,242</td><td>1.00 (Reference)</td></tr><tr><td>7.4–9.8</td><td>413</td><td>312,804</td><td>0.93 (0.81, 1.07)</td></tr><tr><td>9.8–12.3</td><td>357</td><td>316,721</td><td>0.81 (0.69, 0.94)</td></tr><tr><td>12.3–15.7</td><td>370</td><td>318,704</td><td>0.84 (0.72, 1.00)</td></tr><tr><td>>15.7</td><td>379</td><td>318,884</td><td>0.87 (0.72, 1.06)</td></tr><tr><td><i>p-trend</i></td><td></td><td></td><td>0.08</td></tr><tr><td colspan="4">Pectin (g/day)</td></tr><tr><td><1.4</td><td>399</td><td>303,832</td><td>1.00 (Reference)</td></tr><tr><td>1.4–2.0</td><td>397</td><td>313,746</td><td>0.97 (0.84, 1.12)</td></tr><tr><td>2.0–2.6</td><td>379</td><td>316,302</td><td>0.92 (0.79, 1.06)</td></tr><tr><td>2.6–3.5</td><td>396</td><td>318,847</td><td>0.97 (0.83, 1.13)</td></tr><tr><td>>3.5</td><td>381</td><td>316,626</td><td>0.94 (0.80, 1.11)</td></tr><tr><td><i>p-trend</i></td><td></td><td></td><td>0.56</td></tr></table> |
9464465f3d11eb2c0ae7ee9ee31025a79b1a22fa777b8678de6277b4693eb658.png | simple | <table><tr><td>Mycotoxins</td><td>Positives (N)</td><td>Occurrence (%)</td><td>Mean (μg kg<sup>−1</sup>)</td><td>Median (μg kg<sup>−1</sup>)</td><td>Range (μg kg<sup>−1</sup>)</td></tr><tr><td>Raisins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TeA</td><td>20</td><td>35.1</td><td>104.8</td><td>29.4</td><td>6.9~594.4</td></tr><tr><td>AOH</td><td>3</td><td>5.3</td><td>8.9</td><td>7.5</td><td>3.5~15.6</td></tr><tr><td>AME</td><td>11</td><td>19.3</td><td>3.1</td><td>0.4</td><td>0.3~13.5</td></tr><tr><td>OTA</td><td>11</td><td>19.3</td><td>1.9</td><td>0.4</td><td>0.2~8.8</td></tr><tr><td>OTB</td><td>2</td><td>3.5</td><td>0.2</td><td>0.2</td><td>0.1~0.3</td></tr><tr><td>MPA</td><td>27</td><td>47.4</td><td>130.7</td><td>9.4</td><td>0.3~2647.3</td></tr><tr><td>Dried apricots</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TeA</td><td>21</td><td>37.5</td><td>237.1</td><td>71.8</td><td>10.4~1231.8</td></tr><tr><td>TEN</td><td>4</td><td>7.1</td><td>14.0</td><td>12.6</td><td>2.7~28.0</td></tr><tr><td>AME</td><td>3</td><td>5.4</td><td>1.3</td><td>1.2</td><td>0.5~2.1</td></tr><tr><td>PAT</td><td>1</td><td>1.8</td><td>30.6</td><td>30.6</td><td>30.6</td></tr><tr><td>MPA</td><td>15</td><td>26.8</td><td>26.7</td><td>3.9</td><td>1.0~119.7</td></tr><tr><td>Dried dates</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TeA</td><td>18</td><td>34.0</td><td>873.2</td><td>555.0</td><td>9.6~4411.4</td></tr><tr><td>TEN</td><td>7</td><td>13.2</td><td>6.2</td><td>5.2</td><td>1.4~11.2</td></tr><tr><td>PA</td><td>14</td><td>26.4</td><td>39.1</td><td>35.2</td><td>20.4~85.6</td></tr><tr><td>MPA</td><td>1</td><td>1.9</td><td>7.5</td><td>7.5</td><td>7.5</td></tr><tr><td>Dried wolfberries</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TeA</td><td>35</td><td>64.8</td><td>574.8</td><td>93.4</td><td>23.8~5665.3</td></tr><tr><td>TEN</td><td>34</td><td>63.0</td><td>156.5</td><td>75.9</td><td>11.7~1032.6</td></tr><tr><td>AOH</td><td>2</td><td>3.7</td><td>16.6</td><td>16.6</td><td>5.9~27.4</td></tr><tr><td>AME</td><td>4</td><td>7.4</td><td>3.9</td><td>0.3</td><td>0.2~15.0</td></tr></table> |
60860fbc48b84060f25a21224a45a11e5aa7ab54046e3012178fffde1b04a057.png | simple | <table><tr><td>Subject terms</td><td>Titles</td></tr><tr><td>synuclein</td><td>alpha-synuclein</td></tr><tr><td>alpha synuclein</td><td></td></tr><tr><td>alpha</td><td></td></tr><tr><td>protein</td><td></td></tr><tr><td>aggregation</td><td></td></tr><tr><td>deep brain</td><td>deep brain stimulation</td></tr><tr><td>deep</td><td></td></tr><tr><td>stimulation</td><td></td></tr><tr><td>brain stimulation</td><td></td></tr><tr><td>subthalamic</td><td></td></tr><tr><td>lewy</td><td>lewy bodies</td></tr><tr><td>lewy bodies</td><td></td></tr><tr><td>bodies</td><td></td></tr><tr><td>lewy body</td><td></td></tr><tr><td>dementia</td><td></td></tr><tr><td>monoamine oxidase</td><td>monoamine oxidase</td></tr><tr><td>oxidase</td><td></td></tr><tr><td>monoamine</td><td></td></tr><tr><td>mao</td><td></td></tr><tr><td>b</td><td></td></tr><tr><td>mitochondrial</td><td>oxidative stress</td></tr><tr><td>oxidative</td><td></td></tr><tr><td>complex i</td><td></td></tr><tr><td>oxidative stress</td><td></td></tr><tr><td>stress</td><td></td></tr></table> |
09b5ffa2fd874e5d6c5a6e249ce1ade206ce29719d43f0b4d8f22e694e3f7521.png | simple | <table><tr><td>Score</td><td>Criteria</td></tr><tr><td>0</td><td>Active and positive engagement with the assessor or a positive response to the stimuli introduced</td></tr><tr><td>1</td><td>Relaxed or passive response</td></tr><tr><td>2</td><td>Acceptance after a few attempts and eventual tolerance</td></tr><tr><td>3</td><td>Overexcitement</td></tr><tr><td>4</td><td>Dog was attempting to avoid the assessor or the stimuli or used mouthing</td></tr><tr><td>5</td><td>Exhibition of fear, tonic immobility, or escape from the arena</td></tr></table> |
8f1f625682040379560e14c3aefb4c290f634333403b64add3d5b8dbb76af5c5.png | simple | <table><tr><td>Organisms</td><td>Patients</td></tr><tr><td>Coagulase-negative Staph.</td><td>14 (35%)</td></tr><tr><td>Staph. Aureus`</td><td>7 (17.5%)</td></tr><tr><td>Gram-negative rods</td><td>5 (12.5%)</td></tr><tr><td>Enterococcus</td><td>2 (5%)</td></tr><tr><td>Coliform Bacilli</td><td>3 (7.5%)</td></tr><tr><td>Diphteroid Bacilli</td><td>1 (2.5%)</td></tr><tr><td>No Pathogens identified</td><td>8 (20%)</td></tr></table> |
e83c5a76607c6d33bd6382cfd0bdb10039e7d3176175558fb38fa42223a85f0e.png | complex | <table><tr><td>Adverse effect</td><td>Outcome</td><td colspan="2">Upper risk limit (%)</td></tr><tr><td></td><td></td><td>Low-dose methylprednisolone</td><td>High-dose methylprednisolone</td></tr><tr><td rowspan="2">Acute severe allergy</td><td>Lethal</td><td>0.24</td><td>0.00<sup>a</sup></td></tr><tr><td>Life-threatening</td><td>2.65</td><td>1.18</td></tr><tr><td rowspan="3">Cardio-pulmonary distress</td><td>Lethal</td><td>0.33</td><td>0.79</td></tr><tr><td>Persistent</td><td>0.02</td><td>0.39</td></tr><tr><td>Life-threatening</td><td>0.86</td><td>1.71</td></tr><tr><td rowspan="3">Diabetes</td><td>Lethal</td><td>0.02</td><td>0.53</td></tr><tr><td>Persistent</td><td>0.86</td><td>1.05</td></tr><tr><td>Life-threatening</td><td>0.07</td><td>0.13</td></tr><tr><td rowspan="3">Gastrointestinal haemorrhage</td><td>Lethal</td><td>0.26</td><td>0.39</td></tr><tr><td>Persistent</td><td>0.13</td><td>0.13</td></tr><tr><td>Life-threatening</td><td>0.37</td><td>0.79</td></tr><tr><td rowspan="3">Hepatotoxicity</td><td>Lethal</td><td>0.11</td><td>0.13</td></tr><tr><td>Persistent</td><td>0.11</td><td>0.53</td></tr><tr><td>Life-threatening</td><td>0.29</td><td>0.66</td></tr><tr><td rowspan="2">Myopathy</td><td>Persistent</td><td>0.46</td><td>0.79</td></tr><tr><td>Life-threatening</td><td>0.07</td><td>0.13</td></tr><tr><td>Osteonecrosis<sup>b</sup></td><td>Persistent</td><td>0.57</td><td>1.58</td></tr><tr><td>Pancreatitis</td><td>Lethal</td><td>0.04</td><td>0.13</td></tr><tr><td rowspan="2">Psychosis</td><td>Persistent</td><td>0.04</td><td>0.13</td></tr><tr><td>Life-threatening</td><td>0.07</td><td>0.13</td></tr><tr><td rowspan="3">Seizure</td><td>Lethal</td><td>0.09</td><td>0.39</td></tr><tr><td>Persistent</td><td>0.13</td><td>0.00<sup>a</sup></td></tr><tr><td>Life-threatening</td><td>0.13</td><td>0.13</td></tr><tr><td rowspan="3">Ventricular arrhythmia/cardiac arrest</td><td>Lethal</td><td>0.55</td><td>1.05</td></tr><tr><td>Persistent</td><td>0.09</td><td>0.13</td></tr><tr><td>Life-threatening</td><td>0.86</td><td>1.18</td></tr><tr><td rowspan="3">Total<sup>c</sup></td><td>Lethal</td><td>1.65</td><td>3.42</td></tr><tr><td>Persistent</td><td>2.43</td><td>4.73</td></tr><tr><td>Life-threatening</td><td>5.36</td><td>6.04</td></tr></table> |
204aca128b68f985bb2d7f2c37a837bcc7e1667fe206b5284f8309c926a4cf04.png | complex | <table><tr><td rowspan="2">Location</td><td rowspan="2">Year</td><td rowspan="2"><i>N</i></td><td colspan="3">Genotype frequency</td><td>HWE<sup>a</sup></td><td></td></tr><tr><td>Phe/Phe</td><td>Phe/Cys</td><td>Cys/Cys</td><td><i>χ</i><sup>2</sup></td><td><i>P</i></td></tr><tr><td>Porto Velho (RO)</td><td>2010</td><td>37</td><td>0.95</td><td>0.05</td><td>0</td><td>0.002</td><td>0.821</td></tr><tr><td>Rondonópolis (MT)</td><td>2012</td><td>11</td><td>1</td><td>0</td><td>0</td><td>–</td><td>–</td></tr><tr><td>Cianorte (PR)</td><td>2009</td><td>16</td><td>1</td><td>0</td><td>0</td><td>–</td><td>–</td></tr><tr><td>Foz do Iguaçu (PR)</td><td>2009</td><td>24</td><td>0.79</td><td>0.21</td><td>0</td><td>0.324</td><td>0.875</td></tr><tr><td>Maringá (PR)</td><td>2012</td><td>24</td><td>0.87</td><td>0.13</td><td>0</td><td>0.107</td><td>0.753</td></tr><tr><td>Marilena (PR)</td><td>2014</td><td>16</td><td>0.94</td><td>0.06</td><td>0</td><td>0.017</td><td>0.874</td></tr><tr><td>Nova Londrina (PR)</td><td>2014</td><td>21</td><td>1</td><td>0</td><td>0</td><td>–</td><td>–</td></tr><tr><td>Alvorada do Sul (PR)</td><td>2014</td><td>17</td><td>1</td><td>0</td><td>0</td><td>–</td><td>–</td></tr><tr><td>PR</td><td>2009–2014</td><td>118</td><td>0.92</td><td>0.08</td><td>0</td><td>0.185</td><td>0.768</td></tr></table> |
8c9cdc6896b0705a2667fabde76017f50bfceb135a60e49d94154345e979ba8b.png | simple | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td>Classification</td><td>Domain <i>Bacteria</i></td><td>TAS [7]</td></tr><tr><td></td><td></td><td>Phylum <i>Firmicutes</i></td><td>TAS [8–10]</td></tr><tr><td></td><td></td><td>Class <i>Firmibacteria</i></td><td>TAS [8, 9, 11]</td></tr><tr><td></td><td></td><td>Order <i>Bacillales</i></td><td>TAS [8, 9, 12, 13]</td></tr><tr><td></td><td></td><td>Family <i>Bacillaceae</i></td><td>TAS [8, 9, 13, 14]</td></tr><tr><td></td><td></td><td>Genus <i>Bacillus</i></td><td>TAS [8, 9, 13, 15]</td></tr><tr><td></td><td></td><td>Species <i>Bacillus cereus</i></td><td>TAS [8, 9, 13, 16]</td></tr><tr><td></td><td></td><td>Strain FORC_005</td><td></td></tr><tr><td></td><td>Gram stain</td><td>Positive</td><td>TAS [17, 18]</td></tr><tr><td></td><td>Cell shape</td><td>Rod</td><td>TAS [17, 18]</td></tr><tr><td></td><td>Motility</td><td>Motile with peritrichous flagella</td><td>TAS [17, 18]</td></tr><tr><td></td><td>Sporulation</td><td>Endospore-forming</td><td>TAS [8]</td></tr><tr><td></td><td>Temperature range</td><td>10 °C–50 °C</td><td>TAS [8, 17]</td></tr><tr><td></td><td>Optimum temperature</td><td>28–35 °C</td><td>TAS [8]</td></tr><tr><td></td><td>pH range; Optimum</td><td>4.9–9.3; 6.0–7.0</td><td>TAS [17]</td></tr><tr><td></td><td>Carbon source</td><td>Glucose, Aesculin</td><td>TAS [19]</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Ubiquitous; especially in soil</td><td>TAS [17, 18]</td></tr><tr><td>MIGS-6.3</td><td>Salinity</td><td>0–7.5 % NaCl (w/v)</td><td>TAS [17]</td></tr><tr><td>MIGS-22</td><td>Oxygen requirement</td><td>Facultative anaerobes</td><td>TAS [17, 18]</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>free-living</td><td>NAS</td></tr><tr><td>MIGS-14</td><td>Pathogenicity</td><td>Diarrhea, emesis in human</td><td>NAS</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Incheon, South Korea</td><td>IDA</td></tr><tr><td>MIGS-23</td><td>Isolation</td><td>Korean soy sauce braised fish-cake with quail-egg</td><td>IDA</td></tr><tr><td>MIGS-5</td><td>Sample collection</td><td>March 2014</td><td>IDA</td></tr><tr><td>MIGS-4.1</td><td>Latitude</td><td>37.27 N</td><td>IDA</td></tr><tr><td>MIGS-4.2</td><td>Longitude</td><td>126.42 E</td><td>IDA</td></tr><tr><td>MIGS-4.4</td><td>Altitude</td><td>Not reported</td><td></td></tr></table> |
e65d6884f0907d132bf076659d3dfe3cb4b0fbf84551fc3ac4993d82368b5c88.png | simple | <table><tr><td>RAFK, RAF-RAFK</td></tr><tr><td>RAFPH, RAFPH-RAF~{p1}</td></tr><tr><td>RAF, MEK-RAF~{p1}, RAF-RAFK, RAFPH-RAF~{p1}, MEK~{p1}-RAF~{p1}, RAF~{p1}</td></tr><tr><td>MEKPH, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2}</td></tr><tr><td>MEK, MAPK-MEK~{p1, p2}, MEK-RAF~{p1}, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2}, MAPK~{p1}-MEK~{p1, p2}, MEK~{p1}-RAF~{p1}, MEK~{p1}, MEK~{p1, p2}</td></tr><tr><td>MAPKPH, MAPKPH-MAPK~{p1}, MAPKPH-MAPK~{p1, p2}</td></tr><tr><td>MAPK, MAPK-MEK~{p1, p2}, MAPKPH-MAPK~{p1}, MAPK~{p1, p2} MAPK~{p1}-MEK~{p1, p2}, MAPK~{p1}, MAPKPH-MAPK ~{p1, p2},</td></tr></table> |
6609898c396d8cc4db3a67f2673c351ce5f67e28d72487b696ba7cefe8d4954f.png | simple | <table><tr><td>Comparison</td><td></td><td>χ<sup>2</sup> statistics</td><td><i>p</i>-value</td></tr><tr><td>IPI vs. NCCN-IPI</td><td>IPI</td><td>6.46</td><td>0.0110</td></tr><tr><td></td><td>NCCN-IPI</td><td>1.69</td><td>0.1941</td></tr><tr><td>IPI vs. GELTAMO-IPI</td><td>IPI</td><td>10.32</td><td>0.0013</td></tr><tr><td></td><td>GELTAMO-IPI</td><td>3.25</td><td>0.0712</td></tr><tr><td>NCCN-IPI vs. GELTAMO-IPI</td><td>NCCN-IPI</td><td>0.06</td><td>-<sup>*</sup></td></tr><tr><td></td><td>GELTAMO-IPI</td><td>1.60</td><td>-<sup>*</sup></td></tr></table> |
7925f0aa29716fb5bae1bbce2d52726c7a225e889c9e9c789bf5c785e9632d40.png | simple | <table><tr><td>Animals</td><td>Saline</td><td>TNBS alone</td><td>TNBS + RTP</td></tr><tr><td>SD rats</td><td>31.5 ± 2.16</td><td>41.8 ± 3.22</td><td>31.9 ± 1.18</td></tr><tr><td>BALB/c mice</td><td>33.7 ± 1.13</td><td>42.9 ± 2.20</td><td>35.1 ± 3.24</td></tr></table> |
d1ca7174cf470b65761f77d3c54a5b17991aab9f87d19e102a6f8466bf5663d1.png | simple | <table><tr><td>Impact point</td><td><i>P</i><sub>C</sub> (kPa)</td><td><i>P</i><sub>CC</sub> (kPa)</td><td><i>σ</i><sub>VM</sub> (kPa)</td><td><i>τ</i> (kPa)</td></tr><tr><td>A1</td><td>755</td><td>−297</td><td>34.7</td><td>18.8</td></tr><tr><td>A2</td><td>767</td><td>−558</td><td>36.3</td><td>19.4</td></tr><tr><td>A3</td><td>721.7</td><td>−407.7</td><td>36.5</td><td>19.7</td></tr><tr><td>A4</td><td>772</td><td>−355</td><td>37.6</td><td>20.7</td></tr><tr><td>A5</td><td>737</td><td>−426.5</td><td>37.17</td><td>20.6</td></tr><tr><td>B1</td><td>711</td><td>−550</td><td>33.5</td><td>18</td></tr><tr><td>B2</td><td>691.9</td><td>−546.6</td><td>36.4</td><td>19.5</td></tr><tr><td>B3</td><td>1066</td><td>−428</td><td>36.8</td><td>19.9</td></tr><tr><td>B4</td><td>786</td><td>−374</td><td>37.4</td><td>20.6</td></tr><tr><td>B5</td><td>782</td><td>424.6</td><td>37.4</td><td>20.9</td></tr><tr><td>C1</td><td>700</td><td>−338</td><td>34.7</td><td>18.6</td></tr><tr><td>C2</td><td>731</td><td>−362</td><td>35.3</td><td>18.9</td></tr><tr><td>C3</td><td>723.7</td><td>−399</td><td>37</td><td>20.1</td></tr><tr><td>C4</td><td>761</td><td>−428.8</td><td>37.1</td><td>20.5</td></tr><tr><td>C5</td><td>881</td><td>−459</td><td>37.9</td><td>21.1</td></tr></table> |
dc33e9a845d37f7ed8f98d7098324e17317dad2886eb59142aa05f9132a56ff8.png | complex | <table><tr><td></td><td colspan="4">Fourier Descriptor-Based</td><td colspan="4">GEI-Based</td><td colspan="4">Convexity Defect-Based</td></tr><tr><td>Behavior</td><td>TPR</td><td>PPV</td><td>ACC</td><td>F_Score</td><td>TPR</td><td>PPV</td><td>ACC</td><td>F_Score</td><td>TPR</td><td>PPV</td><td>ACC</td><td>F_Score</td></tr><tr><td>Walking</td><td>0</td><td>0</td><td>1.6</td><td>-</td><td>83.9</td><td>97.7</td><td>82.4</td><td>90.3</td><td>17.4</td><td>98.4</td><td>18.4</td><td>29.6</td></tr><tr><td>Running</td><td>13.0</td><td>97.2</td><td>16.0</td><td>22.9</td><td>0</td><td>0</td><td>3.5</td><td>-</td><td>23.4</td><td>98.4</td><td>27.6</td><td>37.8</td></tr><tr><td>Standing</td><td>85.9</td><td>100</td><td>85.9</td><td>92.4</td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td></tr><tr><td>Sitting</td><td>59.7</td><td>100</td><td>59.7</td><td>74.8</td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td></tr><tr><td>Waving with two hands</td><td>81.4</td><td>13.7</td><td>47.8</td><td>23.5</td><td>96.5</td><td>19.1</td><td>59.6</td><td>31.9</td><td>89.0</td><td>68.6</td><td>94.9</td><td>77.4</td></tr><tr><td>Waving with one hand</td><td>78.2</td><td>13.8</td><td>50.3</td><td>23.5</td><td>21.2</td><td>10.1</td><td>73.8</td><td>13.7</td><td>34.9</td><td>73.4</td><td>92.4</td><td>47.3</td></tr><tr><td>Punching</td><td>27.1</td><td>20.3</td><td>74.6</td><td>23.2</td><td>62.2</td><td>16.5</td><td>50.1</td><td>26.1</td><td>39.7</td><td>55.7</td><td>86.9</td><td>46.4</td></tr><tr><td>Lying down</td><td>12.9</td><td>72.0</td><td>38.6</td><td>21.9</td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td><td><i>n/a</i></td></tr><tr><td>Kicking</td><td>61.1</td><td>42.0</td><td>78.7</td><td>49.8</td><td>24.7</td><td>80.7</td><td>86.0</td><td>37.8</td><td>29.3</td><td>47.6</td><td>82.2</td><td>36.3</td></tr><tr><td>Average</td><td>46.6</td><td>51.0</td><td>50.4</td><td>48.7</td><td>55.5</td><td>46.3</td><td>65.1</td><td>50.5</td><td>47.7</td><td>77.4</td><td>71.8</td><td>59.0</td></tr></table> |
36000c0aaf59fbb2ca3e17c9bc6b2fb5786d1521f350fe710d5a7152553729e2.png | simple | <table><tr><td>IOFB location</td><td>Number of cases (%)</td></tr><tr><td>In the vitreous</td><td>11 (52.38 %)</td></tr><tr><td>In the retina</td><td>7 (33.33 %)</td></tr><tr><td>Perforating</td><td>3 (14.28 %)</td></tr></table> |
c5608308e640297affa07e148d8b914ee66336ae5601a9a20159edb87e8520fa.png | complex | <table><tr><td>Groups</td><td colspan="4">Time points</td><td>p-value<sup>1</sup></td><td>p-value<sup>2</sup></td></tr><tr><td> </td><td>Baseline n = 87</td><td>4 months n = 76</td><td>8 months n = 74</td><td>12 months* n = 69</td><td> </td><td> </td></tr><tr><td> </td><td colspan="4">MMSE ± SD**</td><td> </td><td> </td></tr><tr><td>Stimulation therapy</td><td>22.9 ± 4.5</td><td>22.2 ± 5.1</td><td>23.0 ± 4.0</td><td>22.7 ± 4.8</td><td>0.040</td><td>0.0016</td></tr><tr><td>Donepezil</td><td>23.7 ± 3.7</td><td>23.8 ± 3.8</td><td>25.1 ± 3.0</td><td>23.6 ± 3.8</td><td> </td><td> </td></tr><tr><td> </td><td colspan="4">Clock Drawing Test ± SD**</td><td> </td><td> </td></tr><tr><td>Stimulation therapy</td><td>2.8 ± 1.3</td><td>2.9 ± 1.2</td><td>2.8 ± 1.0</td><td>2.9 ± 1.1</td><td>0.940</td><td>0.713</td></tr><tr><td>Donepezil</td><td>2.8 ± 1.3</td><td>2.7 ± 1.3</td><td>2.8 ± 1.2</td><td>2.9 ± 1.1</td><td> </td><td> </td></tr><tr><td> </td><td colspan="4">ADAS-cog ± SD**</td><td> </td><td> </td></tr><tr><td>Stimulation therapy</td><td>18.5 ± 8.7</td><td>17.9 ± 8.6</td><td>16.7 ± 8.8</td><td>17.6 ± 8.6</td><td>0.225</td><td>0.060</td></tr><tr><td>Donepezil</td><td>17.6 ± 5.8</td><td>15.8 ± 6.9</td><td>15.1 ± 7.9</td><td>16.7 ± 8.1</td><td> </td><td> </td></tr></table> |
fe758154680912fe75a06c1b44637655ca92594c6f14e136060d47b468f42d63.png | complex | <table><tr><td>Type of interview</td><td>In-depth interviews</td><td>Focus group discussions</td></tr><tr><td colspan="3"><i>Members of HIV serodiscordant couples</i></td></tr><tr><td>N</td><td>42</td><td>25 (total participants – 4FGDs)</td></tr><tr><td>Age, Median (IQR)</td><td>31 (28–38)</td><td>32(28–35)</td></tr><tr><td>% Female</td><td>21 (50%)</td><td>14 (56%)</td></tr><tr><td>% HIV positive</td><td>21 (50%)</td><td>20 (80%)</td></tr><tr><td>Children, Median (IQR)</td><td>1 (1–2)</td><td>1 (0–1)</td></tr><tr><td colspan="3"><i>Providers (participating in key informant interviews)</i></td></tr><tr><td>N</td><td colspan="2">20</td></tr><tr><td>Gynaecologist</td><td>11 (55%)</td><td> </td></tr><tr><td> Fertility clinics</td><td colspan="2">5</td></tr><tr><td> Jointly public and private clinics</td><td colspan="2">4</td></tr><tr><td> Safer conception research sites</td><td colspan="2">2</td></tr><tr><td>Nurse counsellors</td><td colspan="2">5 (25%)</td></tr><tr><td> Safer conception research sites</td><td colspan="2">3</td></tr><tr><td> Public health hospitals</td><td colspan="2">2</td></tr><tr><td>Clinical Officers</td><td colspan="2">2 (10%)</td></tr><tr><td> Safer conception research sites</td><td colspan="2">1</td></tr><tr><td> Public health hospitals</td><td colspan="2">1</td></tr><tr><td>Counsellors</td><td colspan="2">2 (10%)</td></tr></table> |
e585ae6518a293ddbf3609ba370810c6de444a8029bf3575bdaa66662a484d65.png | simple | <table><tr><td>Sampling sites</td><td>Functional type</td><td>Vehicle and personnel</td><td>Greenbelt coverage rate</td><td>Air pollution</td></tr><tr><td>SSC</td><td>Shed used to stay chicken waiting for slaughtering</td><td>A few transport vehicles with chickens about 10 times h<sup>−1</sup></td><td>~50%</td><td>Serious air pollution</td></tr><tr><td>EPV</td><td>Entrances to personnel and transport vehicles with products</td><td>Flow of transport vehicles, and some flow of personnel at commuting time</td><td><5%</td><td>A little air pollution</td></tr><tr><td>GB</td><td>Green belt</td><td>Little flow of vehicles and personnel</td><td>>95%</td><td>Little air pollution</td></tr></table> |
8ff289859f06f779f727a79e758e48f05d80f52d50b9f4868d04a270b2f0b814.png | simple | <table><tr><td><i>COL4A3</i> polymorphism</td><td>PolyPhen prediction (score)</td><td>SIFT prediction (score)</td></tr><tr><td>G43R</td><td>possibly damaging (1.800)</td><td>not tolerated (0.00)</td></tr><tr><td>P141L</td><td>probably damaging (2.250)</td><td>tolerated (0.40)</td></tr><tr><td>E162G</td><td>benign(0.024)</td><td>tolerated (0.64)</td></tr><tr><td>D326Y</td><td>probably damaging (2.025)</td><td>tolerated (0.08)</td></tr><tr><td>H451R</td><td>benign (1.426)</td><td>tolerated (0.54)</td></tr><tr><td>P574L</td><td>probably damaging (2.250)</td><td>tolerated (0.19)</td></tr><tr><td><i>COL4A4</i> polymorphism</td><td>PolyPhen prediction (score)</td><td>SIFT prediction (score)</td></tr><tr><td>P482S</td><td>benign (1.125)</td><td>tolerated (0.71)</td></tr><tr><td>G545A</td><td>benign (1.350)</td><td>not tolerated (0.01)</td></tr><tr><td>M1327V</td><td>benign(0.017)</td><td>tolerated (0.13)</td></tr></table> |
05a6f86abe6bd9937f885d83970676c7f7a041ad37cd2ab8d50e2b4dfb7ca37f.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Site</td><td rowspan="2">Amino acid replacements</td><td colspan="5">Aminoacid change</td><td>PAML</td></tr><tr><td>SLAC</td><td>REL</td><td>FEL</td><td>MEME</td><td>FUBAR</td><td>Branch-sites</td></tr><tr><td rowspan="7">COX1</td><td>3</td><td>Y; S (2, 12, 14, 21, 22, 23, 24); P (15)</td><td>x</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td></tr><tr><td>177</td><td>T, A (19)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td><i>E. mitis</i></td></tr><tr><td>199</td><td>G; L (2, 6, 7, 14, 15); V (1); A (5, 10)</td><td>–</td><td>–</td><td>–</td><td>x</td><td>x</td><td>–</td></tr><tr><td>363</td><td>T; S (5, 9, 13, 25)</td><td>–</td><td>–</td><td>–</td><td>x</td><td>–</td><td>–</td></tr><tr><td>365</td><td>V; L (2, 6, 7, 14, 18, 21, 23, 24)</td><td>–</td><td>–</td><td>x</td><td>x</td><td>–</td><td>–</td></tr><tr><td>415</td><td>S; I (12)</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>457</td><td>V; I (9, 12)</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="5">COX3</td><td>82</td><td>S; C (3, 17, 18, 19, 20, 21); A (16)</td><td>–</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td></tr><tr><td>135</td><td>I; V (17, 18, 19, 20)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td><i>E. mitis</i></td></tr><tr><td>145</td><td>A; S (16, 22, 24, 25)</td><td>–</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td></tr><tr><td>208</td><td>T; V (2, 6, 7, 14, 24, 25), P (1, 5, 9, 10, 11, 13, 14); A (4, 8); L (12)</td><td>x</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td></tr><tr><td>218</td><td>S; N (3)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td><i>E. brunetti</i></td></tr><tr><td rowspan="4">CYTB</td><td>131</td><td>F, Y (12)</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>185</td><td>F, Y (10)</td><td>–</td><td>x</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>264</td><td>Y; N (10)</td><td>–</td><td>–</td><td>–</td><td>x</td><td>x</td><td><i>E. mitis</i></td></tr><tr><td>347</td><td>V; L (9, 11, 13, 25); A (1, 12, 21); I (3); G (10), T (15)</td><td>x</td><td>–</td><td>x</td><td>–</td><td>x</td><td>–</td></tr></table> |
c9b5eab403e2ce7abdc04cd21790d0b62983fe6f6fcceb2a83d2b01202428b70.png | simple | <table><tr><td>CpG</td><td>A</td><td>B</td><td>V</td><td>Total</td></tr><tr><td>CpG_2</td><td>0.94 (0.93,0.96)</td><td>0.95 (0.93,0.96)</td><td>0.94 (0.92,0.95)</td><td>0.94 (0.93,0.96)</td></tr><tr><td>CpG_3</td><td>0.81 (0.79,0.84)</td><td>0.89 (0.85,0.95)</td><td>0.85 (0.81,0.89)</td><td>0.84 (0.81,0.89)</td></tr><tr><td>CpG_4</td><td>0.33 (0.06,0.63)</td><td>0.39 (0.18,0.63)</td><td>0.36 (0.25,0.75)</td><td>0.35 (0.04,0.63)</td></tr></table> |
a5fbad1e1831797d45d11bfb9f7672489756c0e6d68302918c5918d31fbcaeb9.png | complex | <table><tr><td rowspan="3"></td><td colspan="4">Model <sup>a</sup></td></tr><tr><td colspan="2">Cr in blood <i>(N = 300)</i></td><td colspan="2">Cr in hair (ln) <i>(N = 299)</i></td></tr><tr><td colspan="2">R<sup>2</sup> = 0.135, (<i>p < 0.001</i>)</td><td colspan="2">R<sup>2</sup> = 0.184, (<i>p < 0.001</i>)</td></tr><tr><td><i>Parameter</i></td><td><i>SRC <sup>b</sup></i></td><td><i>p value</i></td><td><i>SRC</i></td><td><i>p value</i></td></tr><tr><td>Exposure dose (ln)</td><td>0.134</td><td><i>0.023</i></td><td>0.226</td><td><i><0.001</i></td></tr><tr><td>Age</td><td>−0.025</td><td><i>0.687</i></td><td>−0.102</td><td><i>0.078</i></td></tr><tr><td>Sex (women)</td><td>0.023</td><td><i>0.714</i></td><td>−0.091</td><td><i>0.124</i></td></tr></table> |
b82c438897d489e315fd60f6152c35e62657623c29c6f7f125774ff80e98d3af.png | complex | <table><tr><td rowspan="2">S/N</td><td rowspan="2">Communities</td><td colspan="4">Number of health facilities</td><td rowspan="2">Population size (2010 projection)</td><td rowspan="2">Major source of water supply</td><td rowspan="2">Means of waste disposal</td><td rowspan="2">Means of faecal disposal</td></tr><tr><td>Public</td><td>Private</td><td>Mission</td><td>Other</td></tr><tr><td>1</td><td>Moniya</td><td>6</td><td>4</td><td>0</td><td>0</td><td>28,990</td><td>• Well water is the major source</td><td>• Indiscriminate dumping at dump sites and drainages</td><td>• Most use latrine at home</td></tr><tr><td rowspan="2">2</td><td rowspan="2">Ojoo</td><td rowspan="2">2</td><td rowspan="2">13</td><td rowspan="2">0</td><td rowspan="2">0</td><td rowspan="2">35,737</td><td rowspan="2">• Well water is the major source</td><td>• Indiscriminate dumping at dump sites and drainages in some areas</td><td rowspan="2">• Most use latrine at home</td></tr><tr><td>• Private refuse collector are engaged by some areas</td></tr><tr><td>3</td><td>Alagbafo</td><td>1</td><td>1</td><td>0</td><td>1</td><td>22,635</td><td>• Well water and spring are the major sources of water although water pipe runs through but disconnected</td><td>• Refuse containers provided by the government</td><td>• Most use latrine at home</td></tr><tr><td>4</td><td>Foko</td><td>1</td><td>3</td><td>0</td><td>0</td><td>29,279</td><td>• Well water is the major source of water although water pipe runs through the community but irregular</td><td>• Indiscriminate dumping at dump sites and drainages in some areas</td><td>• Indiscriminate disposal of fecal matter through the drainage or dumping site</td></tr><tr><td>5</td><td>Inalende</td><td>0</td><td>3</td><td>0</td><td>1</td><td>24,279</td><td>• Well water is the major source of water although water pipe runs through the community but irregular</td><td>• Indiscriminate dumping at dump sites and drainages in some areas</td><td>• Most dispose their fecal matter through the drainage or dump site</td></tr><tr><td rowspan="2">6</td><td rowspan="2">Odo-Ona/Apata</td><td rowspan="2">4</td><td rowspan="2">7</td><td rowspan="2">2</td><td rowspan="2">0</td><td rowspan="2">55,429</td><td>• Pipe borne water irregular</td><td rowspan="2">• Indiscriminate dumping at dump sites and drainages in some areas</td><td rowspan="2">• Most use latrine at home</td></tr><tr><td>• Well water is the major source</td></tr><tr><td>7</td><td>Olorunsogo</td><td>1</td><td>6</td><td>0</td><td>2</td><td>38,475</td><td>• Well water is the major source</td><td>• Indiscriminate dumping at dump sites and drainages in some areas</td><td>• Most use latrine at home</td></tr><tr><td>8</td><td>Olunloyo</td><td>1</td><td>2</td><td>0</td><td>0</td><td>25,531</td><td>• Well water is the major source and some have borehole</td><td>• Indiscriminate dumping at dump sites and drainages in some areas</td><td>• Most use latrine at home</td></tr></table> |
459e4a62f5740f0b056c61ce4573d2ce6029f56da35bcac33fd155c2ee8bc30e.png | complex | <table><tr><td rowspan="2" colspan="2">Assays </td><td colspan="5">Nominal concentration (ng/ml)</td></tr><tr><td>250 </td><td>500 </td><td>1000 </td><td>2000 </td><td>3000 </td></tr><tr><td rowspan="4">Microbiological Intra-assay </td><td>Mean concentration obtained (ng/ml) (<i>n</i>=3) </td><td>345.06 </td><td>600.59 </td><td>873.98 </td><td>1651.43 </td><td>3261.38 </td></tr><tr><td>Precision (SD) </td><td>44.36 </td><td>138.60 </td><td>112.37 </td><td>404.46 </td><td>452.97 </td></tr><tr><td>Precision (RSD, %) </td><td>12.86 </td><td>23.08 </td><td>12.86 </td><td>24.49 </td><td>13.89 </td></tr><tr><td>Accuracy </td><td>138.02 </td><td>120.11 </td><td>87.39 </td><td>82.57 </td><td>108.71 </td></tr><tr><td rowspan="4">Microbiological Inter-assay </td><td>Mean concentration obtained (ng/ml) (<i>n</i>=3) </td><td>327.99 </td><td>464.32 </td><td>870.53 </td><td>1570.46 </td><td>2944.52 </td></tr><tr><td>Precision (SD) </td><td>14.79 </td><td>124.32 </td><td>151.93 </td><td>395.31 </td><td>786.25 </td></tr><tr><td>Precision (RSD, %) </td><td>4.51 </td><td>26.78 </td><td>17.45 </td><td>25.17 </td><td>26.70 </td></tr><tr><td>Accuracy </td><td>131.19 </td><td>92.86 </td><td>87.05 </td><td>78.52 </td><td>98.15 </td></tr><tr><td rowspan="4">HPLC Intra-assay </td><td>Mean concentration obtained (ng/ml) (<i>n</i>=3) </td><td>248.57 </td><td>492.14 </td><td>990.74 </td><td>1994.82 </td><td>2712.25 </td></tr><tr><td>Precision (SD) </td><td>10.59 </td><td>4.33 </td><td>17.08 </td><td>10.95 </td><td>538.64 </td></tr><tr><td>Precision (RSD, %) </td><td>4.26 </td><td>0.88 </td><td>1.72 </td><td>0.55 </td><td>19.86 </td></tr><tr><td>Accuracy </td><td>99.43 </td><td>98.43 </td><td>99.07 </td><td>99.74 </td><td>90.41 </td></tr><tr><td rowspan="4">HPLC Inter-assay </td><td>Mean concentration obtained (ng/ml) (<i>n</i>=3) </td><td>258.56 </td><td>496.34 </td><td>1002.85 </td><td>2002.43 </td><td>3011.78 </td></tr><tr><td>Precision (SD) </td><td>13.15 </td><td>9.03 </td><td>16.17 </td><td>15.11 </td><td>7.80 </td></tr><tr><td>Precision (RSD, %) </td><td>5.08 </td><td>1.82 </td><td>1.61 </td><td>0.75 </td><td>0.26 </td></tr><tr><td>Accuracy </td><td>103.42 </td><td>99.27 </td><td>100.28 </td><td>100.12 </td><td>100.39 </td></tr></table> |
cb05661dd9b39b20c5526d2db3f4f9b568e85ec3eddfc2c92982ecaa85dd647d.png | complex | <table><tr><td>Predictors of HSCL</td><td>Drop-outs at one- year follow-up N = 155</td><td>Participants at one- year follow-up N = 758</td><td>Drop-outs at 15-year follow-up N = 514</td><td>Participants at 15- year follow-up N = 399</td></tr><tr><td colspan="5"><i>Women:</i></td></tr><tr><td> Age</td><td>-.12</td><td>-.17**</td><td>-.14**</td><td>-.18**</td></tr><tr><td> Alone with child</td><td>.19*</td><td>.12**</td><td>.16**</td><td>.09</td></tr><tr><td> Family finances</td><td>-.33**</td><td>-.28**</td><td>-.29**</td><td>-.28**</td></tr><tr><td> Education</td><td>-.15</td><td>-.18**</td><td>-.20**</td><td>-.13**</td></tr><tr><td> Not working</td><td>.16</td><td>.14**</td><td>.14**</td><td>.14**</td></tr><tr><td> Emotionality</td><td>.65**</td><td>.55**</td><td>.53**</td><td>.62**</td></tr><tr><td> Sociability</td><td>-.16*</td><td>-.19**</td><td>-.22**</td><td>-.13*</td></tr><tr><td> Activity</td><td>.00</td><td>-.01</td><td>-.01</td><td>-.01</td></tr><tr><td> Partner support</td><td>-.46**</td><td>-.37**</td><td>-.38**</td><td>-.40**</td></tr><tr><td> Emotional support from friends and family</td><td>-.28**</td><td>-.34**</td><td>-.33**</td><td>-.32**</td></tr><tr><td> Chronic stressors</td><td>.55**</td><td>.54**</td><td>.52**</td><td>.56**</td></tr><tr><td colspan="5"><i>Children:</i></td></tr><tr><td> Activity</td><td>-.04</td><td>-.05</td><td>-.04</td><td>-.05</td></tr><tr><td> Sociability</td><td>-.04</td><td>.03</td><td>.05</td><td>-.02</td></tr><tr><td> Emotionality</td><td>.33**</td><td>.22**</td><td>.26**</td><td>.20**</td></tr><tr><td> Shyness</td><td>.11</td><td>.07*</td><td>.07</td><td>.09</td></tr></table> |
c6c87ed3181eb4f01cb2df4fb6c98f2a79556ccd0f193eeef4a5f30e6a3cc677.png | simple | <table><tr><td>Reference</td><td><i>n</i></td><td>Subjects/methods</td><td>Exposure Measurement (PC; CC, CS)</td><td>Intervention (RCT)</td><td>Cancer type</td><td>Gene/s</td><td>Locus</td><td>Effect</td></tr><tr><td><i>Al-Hilal et al.</i>, <i>2013</i> [14]</td><td>367</td><td>6-month RCT/M + F, 45–70 year</td><td></td><td>EPA + DHA; 0.45, 0.9 or 1.9 g/day</td><td></td><td><i>FADS1 + FADS2</i></td><td>rs174537</td><td>↓D5D activity associated with T variant allele; ↑D5D activity in TG, TT with increasing doses; no association for D6D</td></tr><tr><td><i>Fradet et al.</i>, <i>2009</i> [12]</td><td>Control 478; case 466</td><td>CC/M, mean age 65 year</td><td>FFQ</td><td></td><td>Prostate</td><td><i>COX2</i></td><td>rs4648310</td><td>G allele correlated with aggressive PCa when <i>n</i>-3 FA intake was low, and low risk with high intake</td></tr><tr><td><i>Gago-Dominguez et al.</i>, <i>2004</i> [49]</td><td>Control 670; case 258</td><td>CC/F, 45–74 year</td><td>SQ FFQ</td><td></td><td>Breast</td><td><i>GSTM1, GSTT1, GSTP1</i></td><td>multiple</td><td>Lower activity genotypes associated with higher BCa protection with ↑ intake of marine <i>n</i>-3 FA</td></tr><tr><td><i>Habermann et al.</i>, <i>2013</i> [11]</td><td>Control 912; case 712</td><td>CC/M + F, 30–79 year</td><td>CARDIA questionnaire</td><td></td><td>Rectal</td><td><i>ALOX12</i></td><td>rs11571339</td><td>G allele associated with↓rectal cancer risk in those with low <i>n</i>-3 PUFA intake (NS)</td></tr><tr><td><i>Habermann et al.</i>, <i>2013</i> [11]</td><td>Control 1900; case 1543</td><td>CC/M + F, 30–79 year</td><td>CARDIA questionnaire</td><td></td><td>Colon</td><td><i>ALOX15</i></td><td>rs11568131</td><td>AA genotype have ↓risk of colon cancer with↑ intakes of <i>n</i>-3 PUFA (NS)</td></tr><tr><td><i>Habermann et al.</i>, <i>2013</i> [11]</td><td>Control 1900; case 1543</td><td>CC/M + F, 30–79 year</td><td>CARDIA questionnaire</td><td></td><td>Colon</td><td><i>COX1</i></td><td>rs10306110</td><td>Low EPA/DHA intake associated with higher colon cancer risk in variant allele carriers only</td></tr><tr><td><i>Hedelin et al.</i>, <i>2006</i> [50]</td><td>Control 1130; case1499</td><td>CC/M, 35–79 year</td><td>FFQ</td><td></td><td>Prostate</td><td><i>COX2</i></td><td>rs5275</td><td>C allele at locus rs5275 correlated with ↓risk of PCa with high intake of fatty fish</td></tr><tr><td><i>Hester et al.</i>, <i>2014</i> [13]</td><td>30</td><td>CS/Caucasian F, 21–65 year</td><td>Serum FA</td><td></td><td></td><td><i>FADS1</i></td><td>rs174537</td><td>T variant correlated with lower AA; GG genotype associated with ↑LTB<sub>4</sub> + 5-HETE</td></tr><tr><td><i>Hog et al.</i>, <i>2013</i> [37]</td><td>122</td><td>3 year PC/M, 35–59 year</td><td>Blood serum</td><td></td><td></td><td><i>FADS1, FADS2 + FADS3</i></td><td>rs174537 (FADS1); rs174575, rs2727270 (FADS2), rs1000778 (FADS3)</td><td>rs174537GG had ↑AA, AA/DGLA, DPA, LDL, oxLDL + ↓ETA. Rs17453 had↓AA, AA/DGLA, EPA, DPA, EPA/ALA + urinary PGF<sub>2a</sub></td></tr><tr><td><i>Poole et al.</i>, <i>2007</i> [51]</td><td>Control 626; case 716</td><td>CC/M + F, 30–74 year</td><td>FFQ</td><td></td><td>Colorectal</td><td><i>COX1</i></td><td>Phe17Leu</td><td>Modest↓risk of CRC for carriers of P17 with higher fish intake; L17 carriers have ↓risk of CRC with lower intake</td></tr><tr><td><i>Poole et al., 2010</i> [52]</td><td>Control 582; case 483</td><td>CC/M + F, 30–74 year</td><td>FFQ</td><td></td><td>Colorectal</td><td><i>PGES</i></td><td>rs7873087</td><td>Carriers of T allele have ↓risk of CRC with ↑fish intake</td></tr><tr><td><i>Poole et al.</i>, <i>2010</i> [52]</td><td>Control 582; case 483</td><td>CC/M + F, 30–74 year</td><td>FFQ</td><td></td><td>Colorectal</td><td><i>EP4</i></td><td>Val294Ile</td><td>Carriers of Ile variant showed correlation between ↑fish intake and ↑CRC risk</td></tr><tr><td><i>Porenta et al.</i>, <i>2013</i> [53]</td><td>108</td><td>6-month RCT/CRC at risk M + F</td><td>2 day FR + 24 h recall</td><td>Healthy People 2010 diet or Mediterranean diet</td><td>Colon</td><td><i>FADS</i> cluster</td><td>rs174556 and rs174561 in <i>FADS1</i>, rs383445 in <i>FADS2</i> and rs174537 of the <i>FADS1/2</i> intragenic region</td><td>Wild-type alleles associated with lower AA in colonic mucosa in persons on Mediterranean Diet</td></tr></table> |
7d4a4bf2115e9bf08320b5fcb50fea4d8dabab4a33460b9dc94a4bb80a3dd675.png | simple | <table><tr><td>Instrument A</td><td>Time 1</td><td>Time 2</td><td>Intervention</td><td>Time 3</td><td>Difference score</td><td>Exercise test Result</td></tr><tr><td>Subject 1</td><td>8</td><td>9</td><td>Verum</td><td>15</td><td>+6</td><td>Much improved</td></tr><tr><td>Subject 2</td><td>9</td><td>8</td><td>“”</td><td>15</td><td>+7</td><td>Much improved</td></tr><tr><td>Subject 3</td><td>8</td><td>9</td><td>“”</td><td>15</td><td>+6</td><td>Much improved</td></tr><tr><td>Subject 4</td><td>9</td><td>8</td><td>“”</td><td>15</td><td>+7</td><td>Much improved</td></tr><tr><td>Subject 5</td><td>8</td><td>9</td><td>Placebo</td><td>8</td><td>-1</td><td>Unchanged</td></tr><tr><td>Subject 6</td><td>9</td><td>8</td><td>“”</td><td>9</td><td>+1</td><td>Unchanged</td></tr><tr><td>Subject 7</td><td>8</td><td>9</td><td>“”</td><td>8</td><td>-1</td><td>Unchanged</td></tr><tr><td>Subject 8</td><td>9</td><td>8</td><td>“”</td><td>9</td><td>+1</td><td>Unchanged</td></tr><tr><td>Instrument B</td><td>Time 1</td><td>Time 2</td><td></td><td>Time 3</td><td>Difference score</td><td>Exercise test Result</td></tr><tr><td>Subject 1</td><td>5</td><td>5</td><td>Verum</td><td>5</td><td>0</td><td>Much improved</td></tr><tr><td>Subject 2</td><td>9</td><td>9</td><td>“”</td><td>9</td><td>0</td><td>Much improved</td></tr><tr><td>Subject 3</td><td>13</td><td>13</td><td>“”</td><td>13</td><td>0</td><td>Much improved</td></tr><tr><td>Subject 4</td><td>17</td><td>17</td><td>“”</td><td>17</td><td>0</td><td>Much improved</td></tr><tr><td>Subject 5</td><td>5</td><td>5</td><td>Placebo</td><td>5</td><td>0</td><td>Unchanged</td></tr><tr><td>Subject 6</td><td>9</td><td>9</td><td>“”</td><td>9</td><td>0</td><td>Unchanged</td></tr><tr><td>Subject 7</td><td>13</td><td>13</td><td>“”</td><td>13</td><td>0</td><td>Unchanged</td></tr><tr><td>Subject 8</td><td>17</td><td>17</td><td>“”</td><td>17</td><td>0</td><td></td></tr></table> |
0611ebfb00e97cf3cede987ecf63545586618cb4b18fa2d448b60be7a335e3e6.png | complex | <table><tr><td>Reference</td><td>Population</td><td><i>N</i></td><td>RRT</td><td>Mortality</td><td>Prognostic factors for hospital mortality</td></tr><tr><td colspan="6">Mixed population (solid and hematological tumors, including bone marrow transplantation)</td></tr><tr><td rowspan="3">Berghmans et al. (15)</td><td>Solid: 50%</td><td rowspan="3">32</td><td rowspan="3">CVVHDF</td><td>ICU: 50%</td><td rowspan="3">Number of organ failure</td></tr><tr><td>Hemato: 50%</td><td rowspan="2">Hospital: 53%</td></tr><tr><td>BMT: 28%</td></tr><tr><td rowspan="3">Salahudeen et al. (5)</td><td>Solid: 38%</td><td rowspan="3">199</td><td rowspan="3">C-SLED</td><td rowspan="3">Day 30: 65%</td><td rowspan="3">SOFA score, pH, mean blood pressure</td></tr><tr><td>Hemato: 62%</td></tr><tr><td>BMT: 18%</td></tr><tr><td colspan="6">Mixed population (solid and hematological tumors, excluding bone marrow transplantation)</td></tr><tr><td rowspan="3">Maccariello et al. (13)</td><td>Solid: 73%</td><td rowspan="3">118</td><td>IRRT daily conventional</td><td>ICU: 70%</td><td rowspan="3">Number of organ failure</td></tr><tr><td rowspan="2">Hemato: 27%</td><td>IRRT daily extended</td><td rowspan="2">Hospital: 78%</td></tr><tr><td>CRRT</td></tr><tr><td rowspan="3">Darmon et al. (7)</td><td>Solid: 7%</td><td rowspan="3">94</td><td>CRRT</td><td>ICU: 43.6%</td><td rowspan="3">LOD score, late RRT (>24 h after ICU admission)</td></tr><tr><td>Hemato: 78%</td><td rowspan="2">IRRT</td><td>Hospital: 51.1%</td></tr><tr><td>Other: 15%</td><td>6 months: 65.4%</td></tr><tr><td rowspan="3">Soares et al. (14)</td><td>Solid: 75%</td><td rowspan="3">98</td><td>IRRT conventional</td><td rowspan="3">Hospital: 64–86%</td><td rowspan="3">–</td></tr><tr><td rowspan="2">Hemato: 25%</td><td>IRRT extended</td></tr><tr><td>CRRT</td></tr><tr><td colspan="6">Hematological tumors</td></tr><tr><td rowspan="2">Letourneau et al. (12)</td><td rowspan="2">BMT: 100%</td><td rowspan="2">14</td><td>CVVHDF</td><td rowspan="2">–</td><td rowspan="2">–</td></tr><tr><td>IRRT</td></tr><tr><td>Lanore et al. (11)</td><td>BMT: 11%</td><td>43</td><td></td><td>ICU: 72%</td><td>ARF secondary to sepsis, SAPS score, mechanical ventilation support</td></tr><tr><td rowspan="3">Benoit et al. (9)</td><td rowspan="3">BMT: 22.4%</td><td rowspan="3">50</td><td>IRRT</td><td>ICU: 79.6%</td><td rowspan="3">–</td></tr><tr><td rowspan="2">CRRT</td><td>Hospital: 83.7%</td></tr><tr><td>6 months: 86%</td></tr></table> |
dbf450420e0ff336febcc9d72d650cfb801904872c2b13c4af0cd186d20531a9.png | simple | <table><tr><td>OCT (<i>μ</i>m) Mean ± SD</td><td>Chloroquine group</td><td>Control group</td><td><i>p</i> value<sup><i>∗</i></sup></td></tr><tr><td>CFT</td><td>238.15 ± 22.5</td><td>248.2 ± 19.05</td><td>0.034</td></tr><tr><td>Parafoveal thickness</td><td> </td><td> </td><td> </td></tr><tr><td> Superior</td><td>310.7 ± 21.64</td><td>322.35 ± 12.02</td><td>0.004</td></tr><tr><td> Inferior</td><td>309.05 ± 18.75</td><td>319.025 ± 11.3</td><td>0.005</td></tr><tr><td> Nasal</td><td>311.45 ± 14.9</td><td>320.05 ± 11.39</td><td>0.005</td></tr><tr><td> Temporal</td><td>299.025 ± 21.67</td><td>320.05 ± 11.39</td><td>0.013</td></tr><tr><td>Perifoveal thickness</td><td> </td><td> </td><td> </td></tr><tr><td> Superior</td><td>287.675 ± 19.9</td><td>286.7 ± 11.85</td><td>0.791</td></tr><tr><td> Inferior</td><td>279.1 ± 17.75</td><td>282.75 ± 10.34</td><td>0.264</td></tr><tr><td> Nasal</td><td>287.38 ± 15.82</td><td>302 ± 11.4</td><td>0.107</td></tr><tr><td> Temporal</td><td>278.15 ± 20.6</td><td>282.6 ± 12.144</td><td>0.243</td></tr><tr><td>RNFL thickness</td><td>111.4458 ± 14.6969</td><td>107.6425 ± 11.5335</td><td>0.202</td></tr><tr><td>GCC thickness</td><td>95.61 ± 6.385</td><td>96.1217 ± 6.1347</td><td>0.716</td></tr><tr><td>FLV</td><td>0.86 ± 1.04</td><td>0.60 ± 0.53</td><td>0.167</td></tr><tr><td>GLV</td><td>4.28 ± 3.87</td><td>3.56 ± 3.05</td><td>0.358</td></tr></table> |
720ec128431eaa828944965c8cc1c61e204f8c12e2850c62c618c3a3a0f84926.png | simple | <table><tr><td>Metal</td><td>PFP soluble metals (μg metal/g PM)</td><td>Fresno soluble metals (μg metal/g PM)b</td></tr><tr><td>Co</td><td>< 3.2</td><td>n/a</td></tr><tr><td>Cr</td><td>< 0.84</td><td>n/a</td></tr><tr><td>Cu</td><td>< 1.0</td><td>344 ± 137</td></tr><tr><td>Fe</td><td>< 25</td><td>262 ± 32</td></tr><tr><td>Mn</td><td>< 1.8</td><td>397 ± 56</td></tr><tr><td>Ni</td><td>< 3.4</td><td>n/a</td></tr><tr><td>V</td><td>< 0.68</td><td>17 ± 3</td></tr><tr><td>Zn</td><td>7.8 ± 4.9</td><td>n/a</td></tr></table> |
d7e87a3782dd10b498799087bd7a732ef164b01f3e5d8e0dd05f0d8aa217d421.png | simple | <table><tr><td></td><td>Before SVA onset (<i>n</i> = 30)</td><td>After SVA onset (<i>n</i> = 30)</td><td><i>p</i></td></tr><tr><td>Systolic arterial pressure, mmHg</td><td>114 [97–127]</td><td>97 [86–118]</td><td>0.076</td></tr><tr><td>Diastolic arterial pressure, mmHg</td><td>58 [51–63]</td><td>58 [47–64]</td><td>0.513</td></tr><tr><td>Mean arterial pressure, mmHg</td><td>77.0 [70.0–87.0]</td><td>73.0 [58.5–80.5]</td><td>0.056</td></tr><tr><td>Arterial pulse pressure, mmHg</td><td>54 [39–70]</td><td>42 [31–57]</td><td>0.081</td></tr><tr><td>Heart rate, beats/min</td><td>99 [87–118]</td><td>140 [123–165]</td><td><0.001</td></tr><tr><td>Dobutamine dose, μg/kg/min<sup>a</sup></td><td>7.5 [5.0–10.0]</td><td>7.5 [5.0–10.0]</td><td>>0.99</td></tr><tr><td>Norepinephrine dose, mg/h<sup>a</sup></td><td>1.7 [0.3–3.0]</td><td>1.8 [0.5–4.5]</td><td>0.010</td></tr><tr><td>Epinephrine dose, mg/h<sup>a</sup></td><td>1.3 [0.5–2.0]</td><td>1.5 [0.0–3.0]</td><td>0.655</td></tr></table> |
64dd02bdcca1c0ab817042e93de32b14d0e9ad988a37b0925227068f058871ab.png | complex | <table><tr><td></td><td>Nest (%)</td><td>Environment (%)</td><td>Chi-square</td><td><i>P</i></td></tr><tr><td colspan="5">Egg stage</td></tr><tr><td> String</td><td>55</td><td>76</td><td>3.366</td><td>0.07</td></tr><tr><td> Foil</td><td>10</td><td>13</td><td>0.391</td><td>0.53</td></tr><tr><td> Paper</td><td>0</td><td>2</td><td>–</td><td>–</td></tr><tr><td> Other</td><td>35</td><td>9</td><td>15.364</td><td>< 0.001</td></tr><tr><td colspan="5">Chick stage</td></tr><tr><td> String</td><td>30</td><td>83</td><td>24.858</td><td>< 0.001</td></tr><tr><td> Foil</td><td>21</td><td>8</td><td>5.828</td><td>0.02</td></tr><tr><td> Paper</td><td>11</td><td>2</td><td>6.231</td><td>0.01</td></tr><tr><td> Other</td><td>38</td><td>7</td><td>21.356</td><td>< 0.001</td></tr></table> |
9030b2f5d0fe3002f25a5d845bc6f6511fb37cf4a7465ae0f5a1d28a6337aebf.png | complex | <table><tr><td></td><td></td><td>Number of clones</td><td>Number of heteroinsertion</td><td>Number of homoinsertion</td><td>Efficiency of heteroinsertion</td><td>Efficiency of homoinsertion</td></tr><tr><td rowspan="2"><i>Eed</i></td><td>LNL insertion</td><td>88</td><td>17</td><td>4</td><td>19.3%</td><td>4.5%</td></tr><tr><td>FNFL insertion</td><td>190</td><td>33</td><td>5</td><td>17.4%</td><td>2.6%</td></tr><tr><td rowspan="2"><i>SRCAP</i></td><td>LNL insertion</td><td>94</td><td>65</td><td>3</td><td>69.1%</td><td>3.2%</td></tr><tr><td>FNFL insertion</td><td>96</td><td>70</td><td>2</td><td>72.9%</td><td>2.1%</td></tr></table> |
5f381ad5f092f463421f960c2cea3c67fae4aa6d5f488394e4007380a092622d.png | simple | <table><tr><td>Donor</td><td>Population</td><td>Expansionday</td><td>EGA sample accessionnumber</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>0</td><td>EGAN00001588556</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>0</td><td>EGAN00001588558</td></tr><tr><td>1</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>0</td><td>EGAN00001588559</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>5</td><td>EGAN00001588560</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>5</td><td>EGAN00001588561</td></tr><tr><td>1</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>5</td><td>EGAN00001588562</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>10</td><td>EGAN00001588563</td></tr><tr><td>1</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>10</td><td>EGAN00001588564</td></tr><tr><td>1</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>10</td><td>EGAN00001588565</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>0</td><td>EGAN00001588549</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>0</td><td>EGAN00001588541</td></tr><tr><td>2</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>0</td><td>EGAN00001588542;EGAN00001588543</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>5</td><td>EGAN00001588575</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>5</td><td>EGAN00001588550</td></tr><tr><td>2</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>5</td><td>EGAN00001588551</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>+</sup></td><td>10</td><td>EGAN00001588552</td></tr><tr><td>2</td><td>IgM<sup>+</sup> IgD<sup>-</sup></td><td>10</td><td>EGAN00001588554</td></tr><tr><td>2</td><td>IgM<sup>-</sup> IgD<sup>-</sup></td><td>10</td><td>EGAN00001588555</td></tr></table> |
00fe8dad30865d3249928e5f3000a17171d8c2782b814e7006f4883f324ec649.png | complex | <table><tr><td></td><td>Total (n = 116)</td><td>Covered (n = 42)</td><td>Uncovered (n = 74)</td><td><i>p </i>value¶</td></tr><tr><td colspan="5">Complication rate</td></tr><tr><td> Stent migration, n(%)</td><td>8(6.9)</td><td>4(9.5)</td><td>4(5.4)</td><td>0.458</td></tr><tr><td> Granulation tissue formation, n(%)</td><td>22(19.0)</td><td>7 (16.7)</td><td>15(20.3)</td><td>0.634</td></tr><tr><td> Stent fracture, n(%)</td><td>19(16.4)</td><td>5(11.9)</td><td>14(18.9)</td><td>0.44</td></tr><tr><td>Resolution of symptoms, n(%)</td><td>89(76.7)</td><td>30 (71.4)</td><td>59 (79.7)</td><td>0.363</td></tr></table> |
b1ff56ba9bcdf759d5837e0fca17a22501c6247ab91186cb6fd85d4245c25962.png | simple | <table><tr><td> </td><td>Hazard ratio</td><td>95% CI</td><td>p</td></tr><tr><td>Model 1*</td><td> </td><td> </td><td> </td></tr><tr><td>Age</td><td>1.02</td><td>1.01-1.03</td><td>0.01</td></tr><tr><td>Heart failure</td><td>1.83</td><td>1.18-2.83</td><td>0.007</td></tr><tr><td>Hemoglobin on admission</td><td>0.91</td><td>0.85-0.98</td><td>0.01</td></tr><tr><td>Model 2**</td><td> </td><td> </td><td> </td></tr><tr><td>Age</td><td>1.02</td><td>1.00-1.04</td><td>0.004</td></tr><tr><td>Peripheral artery disease</td><td>0.56</td><td>0.32-0.98</td><td>0.04</td></tr><tr><td>Hemoglobin at admission</td><td>0.92</td><td>0.85-0.99</td><td>0.02</td></tr><tr><td>CKD</td><td>1.62</td><td>1.09-2.40</td><td>0.02</td></tr><tr><td>Model 1 + SAPS II</td><td> </td><td> </td><td> </td></tr><tr><td>Heart failure</td><td>2.25</td><td>1.29-3.93</td><td>0.005</td></tr><tr><td>Coronary artery disease</td><td>0.40</td><td>0.21-0.77</td><td>0.006</td></tr><tr><td>Hemoglobin on admission</td><td>0.91</td><td>0.84-0.98</td><td>0.009</td></tr><tr><td>SAPS II</td><td>1.04</td><td>1.03-1.05</td><td>0.001</td></tr><tr><td>Model 2 + SAPS II</td><td> </td><td> </td><td> </td></tr><tr><td>Heart failure</td><td>1.70</td><td>0.99-2.88</td><td>0.05</td></tr><tr><td>Peripheral artery disease</td><td>0.51</td><td>0.28-0.95</td><td>0.03</td></tr><tr><td>Coronary artery disease</td><td>0.49</td><td>0.26-0.93</td><td>0.03</td></tr><tr><td>Hemoglobin on admission</td><td>0.91</td><td>0.84-0.98</td><td>0.01</td></tr><tr><td>CKD</td><td>1.67</td><td>1.08-2.57</td><td>0.02</td></tr><tr><td>SAPS II</td><td>1.04</td><td>1.03-1.05</td><td>0.001</td></tr></table> |
d81cc0591e527fff90c9f76529feacf21141f23c3723a64526febc83c3470fc6.png | simple | <table><tr><td>Indexes</td><td>Biological Rope Unit</td><td><i>Myriophyllum verticillatum</i> Unit</td><td><i>Iris wilsonii</i> Unit</td><td>Activated Carbon Unit</td></tr><tr><td>TN</td><td>16.07%</td><td>28.10%</td><td>30.33%</td><td>19.55%</td></tr><tr><td>NO<sub>3</sub><sup>−</sup>-N</td><td>28.64%</td><td>37.02%</td><td>33.78%</td><td>25.03%</td></tr><tr><td>NH<sub>4</sub><sup>+</sup>-N</td><td>17.68%</td><td>25.12%</td><td>29.22%</td><td>28.04%</td></tr><tr><td>TP</td><td>21.19%</td><td>3.96%</td><td>6.05%</td><td>4.17%</td></tr><tr><td>PO<sub>4</sub><sup>3−</sup>-P</td><td>15.05%</td><td>16.51%</td><td>14.23%</td><td>25.52%</td></tr></table> |
f99321a55f59bf69d2ff5cfe23e739a4a8918fe91426e5e1d230a558f364292c.png | complex | <table><tr><td colspan="4">Characteristics</td></tr><tr><td>Characteristics of the children</td><td></td><td>N</td><td>%</td></tr><tr><td>Age (n = 1067)</td><td>- 2 or 3 years old</td><td>227</td><td>21%</td></tr><tr><td></td><td>- 4 years old</td><td>335</td><td>31%</td></tr><tr><td></td><td>- 5 years old</td><td>328</td><td>31%</td></tr><tr><td></td><td>- 6 years old</td><td>177</td><td>17%</td></tr><tr><td>Girls (n = 1068)</td><td></td><td>537</td><td>50%</td></tr><tr><td>First in birth order (n = 1039)</td><td></td><td>498</td><td>48%</td></tr><tr><td>Medical conditions (n = 1068)</td><td>- Preterm infant</td><td>96</td><td>9%</td></tr><tr><td></td><td>- Hospitalisation after birth</td><td>81</td><td>8%</td></tr><tr><td></td><td>- Asthma</td><td>156</td><td>15%</td></tr><tr><td></td><td>- Wearing of glasses</td><td>146</td><td>14%</td></tr><tr><td></td><td>- Auditory disorders</td><td>63</td><td>6%</td></tr><tr><td></td><td>- Allergy</td><td>214</td><td>20%</td></tr><tr><td></td><td>- Behavioural disorder</td><td>44</td><td>4%</td></tr><tr><td></td><td>- At least one surgical intervention</td><td>225</td><td>21%</td></tr><tr><td></td><td>- Other medical conditions</td><td>70</td><td>7%</td></tr><tr><td>Long term medication use (n = 1068)</td><td></td><td>73</td><td>7%</td></tr><tr><td>Frequency of administrating over the counter drugs without medical advice (n = 1062)</td><td>- Never</td><td>168</td><td>16%</td></tr><tr><td></td><td>- Rarely</td><td>311</td><td>29%</td></tr><tr><td></td><td>- Often</td><td>509</td><td>48%</td></tr><tr><td></td><td>- Almost every time my child is ill</td><td>74</td><td>7%</td></tr><tr><td>Under homeopathic treatment (n = 1043)</td><td></td><td>549</td><td>53%</td></tr><tr><td>Advice from a pharmacist within the last 12 months (n = 1051)</td><td></td><td>445</td><td>42%</td></tr><tr><td></td><td></td><td>Mean</td><td>SD</td></tr><tr><td>N. of primary care consultations within the last 12 months (n = 1029)</td><td></td><td>5.9</td><td>4.6</td></tr><tr><td>Parental characteristics</td><td></td><td>N</td><td>%</td></tr><tr><td>Single parent family (n = 1066)</td><td></td><td>136</td><td>13%</td></tr><tr><td>Rural place of residence (n = 1064)</td><td></td><td>217</td><td>20%</td></tr><tr><td>Occupation (n = 1056)</td><td>- Disadvantaged (workers, unemployed)</td><td>151</td><td>14%</td></tr><tr><td></td><td>- Moderately advantaged (self-employed, employees)</td><td>563</td><td>53%</td></tr><tr><td></td><td>- Advantaged (managers and executives)</td><td>342</td><td>33%</td></tr><tr><td>Education level (n = 1037)</td><td>- Elementary and secondary</td><td>285</td><td>27%</td></tr><tr><td></td><td>- High school diploma ("Baccalauréat")</td><td>238</td><td>23%</td></tr><tr><td></td><td>- Lower tertiary</td><td>235</td><td>23%</td></tr><tr><td></td><td>- Higher tertiary</td><td>279</td><td>27%</td></tr><tr><td>Annual family income (n = 949)</td><td>- < 14 000 €</td><td>168</td><td>18%</td></tr><tr><td></td><td>- 14 000 to 19 999 €</td><td>203</td><td>21%</td></tr><tr><td></td><td>- 20 000 to 29 999 €</td><td>286</td><td>30%</td></tr><tr><td></td><td>- 30 000 to 39 999 €</td><td>170</td><td>18%</td></tr><tr><td></td><td>- ≥ 40 000 €</td><td>122</td><td>13%</td></tr><tr><td></td><td></td><td>Mean</td><td>SD</td></tr><tr><td>Age of the respondent in year (n = 1058)</td><td></td><td>34.0</td><td>5.0</td></tr><tr><td>Parental stress level (n = 1040)</td><td></td><td>4.9</td><td>2.3</td></tr></table> |
e684937ad2d8653876151d3b85379399757e07cb0bf6d3943f4e913d5254e049.png | simple | <table><tr><td>Procedure</td><td>Total volume (mL)</td><td>Total protein (mg)</td><td>Total activity (UI)<sup>a</sup></td><td>Specific activity<sup>b</sup> (UI mg<sup>−1</sup>)</td><td>Purification<sup>c</sup> (fold)</td></tr><tr><td>Crude extract</td><td>300</td><td>1302.3</td><td>215220</td><td>165.3</td><td>1</td></tr><tr><td>Ammonium Sulphate ppt.</td><td>22</td><td>43.9</td><td>13501.4</td><td>307.5</td><td>1.86</td></tr><tr><td>Dialysis</td><td>21</td><td>39.2</td><td>12559.9</td><td>320.4</td><td>1.94</td></tr><tr><td>DEAE-cellulose</td><td>12</td><td>6.37</td><td>6811.2</td><td>1069.3</td><td>6.47</td></tr><tr><td>Sephadex G-100</td><td>9</td><td>2.9</td><td>4599.1</td><td>1585.9</td><td>9.6</td></tr></table> |
276677b6d54c18f49b4465d50abcf3e04a6569ff7fe33152b16074b66d36a870.png | complex | <table><tr><td rowspan="2">Gene name</td><td rowspan="2">Gene symbol</td><td rowspan="2">Comments</td><td colspan="2">Statistics</td></tr><tr><td>Log<sub>2</sub> fold change</td><td><i>q</i> value</td></tr><tr><td>Spermidine synthetase</td><td><i>Srm</i></td><td>Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])</td><td>3.68</td><td>0.00016</td></tr><tr><td>Ornithine decarboxylase 1</td><td><i>Odc1</i></td><td>Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])</td><td>2.52</td><td>0.00016</td></tr><tr><td>Spermine synthetase</td><td><i>Sms</i></td><td>Synthesizes polyamines important in granule biogenesis and homesostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])</td><td>0.54</td><td>0.0045</td></tr><tr><td>Basic helix-loop-helix family, member A15</td><td><i>Bhlha15</i></td><td>Important transcription factor in forming mature secretory granules in a variety of specialized secretory cells (Tian 2010 [72])</td><td>3.42</td><td>0.00016</td></tr><tr><td>Rab5c, member of Ras oncogene family</td><td><i>Rab5c</i></td><td>Key regulator of mast cell granule fusion during biogenesis (Azouz 2014 [48])</td><td>0.62</td><td>0.00032</td></tr><tr><td>Mannose-6-phosphate receptor</td><td><i>M6pr</i></td><td>Transports glycosylated proteins, such as lysosomal hydrolases and TNF, into vesicles (Coutinho 2012 [50], Olszewski 2006 [73])</td><td>0.43</td><td>0.00016</td></tr><tr><td>Adaptor protein 1A complex</td><td><i>Ap1m1</i></td><td>Protein necessary for the sorting of proteins into vesicles and secretory granule maturation (Bonnemaison 2014 [49])</td><td>0.36</td><td>0.0033</td></tr><tr><td>ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c</td><td><i>Atp6v0c</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>0.69</td><td>0.00016</td></tr><tr><td>ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H</td><td><i>Atp6v1h</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>0.52</td><td>0.00016</td></tr><tr><td>ATPase, H+ transporting, lysosomal V0 subunit a2</td><td><i>Atp6v0a2</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>0.46</td><td>0.00016</td></tr><tr><td>ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H</td><td><i>Atp6v1a</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>0.42</td><td>0.020</td></tr><tr><td>ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e1</td><td><i>Atp6v0e</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>0.32</td><td>0.0044</td></tr><tr><td>ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D</td><td><i>Atp6v1d</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>−0.24</td><td>0.038</td></tr><tr><td>ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2</td><td><i>Atp6v1g2</i></td><td>Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)</td><td>−1.84</td><td>0.00016</td></tr><tr><td>Lysosomal trafficking regulator</td><td><i>Lyst</i></td><td>Important regulator of granule formation (Durchfort 2012 [95], Hammel 2010 [52])</td><td>−1.29</td><td>0.00016</td></tr><tr><td>Solute carrier family 18, member 2</td><td>Slc18a2</td><td>Transports histamine and serotonin into granules (Merickel 1995 [96])</td><td>−0.92</td><td>0.00016</td></tr></table> |
2ed7b4620c5b6672c3f5c7f3358e1cc9e4d90c91cb15f9a2fbd8213b583f4064.png | complex | <table><tr><td rowspan="2">Factor</td><td rowspan="2">B</td><td rowspan="2">p-value</td><td rowspan="2">OR</td><td colspan="2">95% CI for OR</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td>Age</td><td>.061</td><td>.436</td><td>1.063</td><td>.912</td><td>1.239</td></tr><tr><td>Sex (Female)</td><td>.407</td><td>.488</td><td>1.502</td><td>.476</td><td>4.743</td></tr><tr><td>BMI</td><td>.019</td><td>.755</td><td>1.019</td><td>.904</td><td>1.150</td></tr><tr><td>Medications</td><td>-.118</td><td>.425</td><td>.889</td><td>.665</td><td>1.188</td></tr><tr><td>Comorbidities</td><td>.388</td><td>.093</td><td>1.474</td><td>.938</td><td>2.318</td></tr><tr><td>ASA class</td><td>1.667</td><td>.003*</td><td>5.297</td><td>1.774</td><td>15.817</td></tr><tr><td>Complications</td><td>.918</td><td>.013*</td><td>2.505</td><td>1.210</td><td>5.187</td></tr></table> |
d3e8a42e789a9b37560fd1c22176305b4cd26fb76318857e33cd212d916b6e22.png | simple | <table><tr><td></td><td>Diabetic footpatients</td><td>Diabetics withoutfoot complications</td><td>p</td></tr><tr><td>HbA1c</td><td>8 (7.28-9.40)</td><td>6.85 (6.10-8.00)</td><td>0.018</td></tr><tr><td>CRP</td><td>4 (2.25-5.15)</td><td>2.25 (1.90-3.08)</td><td>0.041</td></tr><tr><td>Total cholesterol (mg/dl)</td><td>215.50 (166,50-243,00)</td><td>204.00 (185,50-210,00)</td><td>0.054</td></tr><tr><td>LDL cholesterol (mg/dl)</td><td>121.70 (98,75-148,75)</td><td>104.50 (78,00-123,00)</td><td>0.032</td></tr><tr><td>Tryglicerids (mg/dl)</td><td>160.50 (119,50-209,25)</td><td>180.50 (144,50-199,00)</td><td>0.012</td></tr><tr><td>Globuli bianchi</td><td>12.675 (10775,00-14140,00)</td><td>10.700 (8850,00-12027,50)</td><td>0.032</td></tr><tr><td>Adiponectin (μg/ml)</td><td>7.1450 (4.47-12.17)</td><td>8.480 (5.15-12.87)</td><td>0.022</td></tr><tr><td>Resistin (ng/ml)</td><td>5.160 (2.96-6.29)</td><td>3.290 (2.37-6.5)</td><td>0.021</td></tr><tr><td>IL-6 (pg/ml)</td><td>3.21 (1.23-5.34)</td><td>2.13 (1.24-3.97)</td><td>0.033</td></tr></table> |
fc23877a2d63efd4900f24a735f4e4609856bca09895a101fce2b6954863c066.png | simple | <table><tr><td>Histone</td><td>Modification 1</td><td>Modification 2</td><td>Modification 3</td><td>Modification 4</td><td>Intensity average 6xHIS-Ibd1 (4 repetitions)</td><td>Intensity average 6xHIS-G9a (2 repetitions)</td></tr><tr><td>H3</td><td><i>K9ac</i></td><td><i>K14ac</i></td><td></td><td></td><td><i>0.95</i></td><td>0.02</td></tr><tr><td>H2a</td><td>K5ac</td><td><i>K9ac</i></td><td><i>K13ac</i></td><td></td><td><i>0.92</i></td><td>0.01</td></tr><tr><td>H4</td><td><i>R3me2s</i></td><td><i>K5ac</i></td><td><i>K8ac</i></td><td><i>K12ac</i></td><td><i>0.90</i></td><td>0.00</td></tr><tr><td>H4</td><td><i>K5ac</i></td><td><i>K8ac</i></td><td><i>K12ac</i></td><td>K16ac</td><td><i>0.89</i></td><td>0.03</td></tr><tr><td>H3</td><td>K9me3</td><td><i>K14ac</i></td><td></td><td></td><td><i>0.88</i></td><td>0.01</td></tr><tr><td>H3</td><td>S10P</td><td><i>K14ac</i></td><td></td><td></td><td><i>0.88</i></td><td>0.04</td></tr><tr><td>H4</td><td><i>K5ac</i></td><td><i>K8ac</i></td><td><i>K12ac</i></td><td></td><td><i>0.84</i></td><td>0.01</td></tr><tr><td>H3</td><td>T11P</td><td><i>K14ac</i></td><td></td><td></td><td><i>0.82</i></td><td>0.01</td></tr><tr><td>H2a</td><td>S1P</td><td>K5ac</td><td><i>K9ac</i></td><td><i>K13ac</i></td><td><i>0.82</i></td><td>0.01</td></tr><tr><td>H2a</td><td>S1P</td><td><i>K9ac</i></td><td><i>K13ac</i></td><td></td><td><i>0.81</i></td><td>0.01</td></tr><tr><td>H3</td><td>R2me2s</td><td>K4me2</td><td>R8me2a</td><td><i>K9me2</i></td><td>0.19</td><td><i>0.96</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4me1</td><td>R8me2a</td><td><i>K9me2</i></td><td>0.18</td><td><i>0.94</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4me2</td><td>R8me2a</td><td><i>K9me2</i></td><td>0.18</td><td><i>0.90</i></td></tr><tr><td>H3</td><td>K4ac</td><td>R8me2s</td><td><i>K9me1</i></td><td></td><td>0.21</td><td><i>0.84</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4me2</td><td>R8me2a</td><td><i>K9me1</i></td><td>0.19</td><td><i>0.83</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4me3</td><td>R8me2a</td><td><i>K9me2</i></td><td>0.18</td><td><i>0.80</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4ac</td><td>R8me2a</td><td><i>K9me2</i></td><td>0.28</td><td><i>0.79</i></td></tr><tr><td>H3</td><td>R2me2a</td><td>K4me3</td><td>R8me2a</td><td><i>K9me1</i></td><td>0.19</td><td><i>0.79</i></td></tr><tr><td>H3</td><td>R2me2s</td><td>K4ac</td><td>R8me2a</td><td><i>K9me1</i></td><td>0.16</td><td><i>0.76</i></td></tr><tr><td>H3</td><td>R2me2s</td><td>K4me2</td><td>R8me2s</td><td><i>K9me1</i></td><td>0.17</td><td><i>0.76</i></td></tr></table> |
af9d63629b7fc738893b6e75a3a7539f6bccd4b376cf18ff9252cf096e1c2874.png | complex | <table><tr><td>Characteristic</td><td>n</td><td>%</td></tr><tr><td>Area of practice</td><td></td><td></td></tr><tr><td>GP/FP</td><td>117</td><td>27</td></tr><tr><td>GP/FP with enhanced area</td><td>72</td><td>17</td></tr><tr><td>Specialist</td><td>219</td><td>51</td></tr><tr><td>Other<sup>1</sup>:</td><td>6</td><td>1</td></tr><tr><td>Not specified</td><td>12</td><td>3</td></tr><tr><td>Number of years in practice</td><td></td><td></td></tr><tr><td>0 to 5</td><td>40</td><td>9</td></tr><tr><td>6 to 10</td><td>39</td><td>9</td></tr><tr><td>11 to 15</td><td>45</td><td>11</td></tr><tr><td>16 to 20</td><td>59</td><td>14</td></tr><tr><td>21 or more</td><td>230</td><td>54</td></tr><tr><td>Not specified</td><td>13</td><td>3</td></tr><tr><td>Region of practice</td><td></td><td></td></tr><tr><td>Atlantic</td><td>38</td><td>9</td></tr><tr><td>Quebec</td><td>100</td><td>23</td></tr><tr><td>Ontario</td><td>128</td><td>30</td></tr><tr><td>Prairies</td><td>70</td><td>16</td></tr><tr><td>BC</td><td>64</td><td>15</td></tr><tr><td>Territories</td><td>6</td><td>1</td></tr><tr><td>Not specified</td><td>20</td><td>5</td></tr><tr><td>Community where practicing</td><td></td><td></td></tr><tr><td>Urban</td><td>226</td><td>53</td></tr><tr><td>Rural</td><td>92</td><td>22</td></tr><tr><td>Both</td><td>96</td><td>23</td></tr><tr><td>Not specified</td><td>12</td><td>3</td></tr><tr><td colspan="2">Language of survey completion</td><td></td></tr><tr><td>English</td><td>388</td><td>91</td></tr><tr><td>French</td><td>38</td><td>9</td></tr></table> |
f2238b414473ddbdbdbe34386afcc87d96ea6a9cfafb4ed8dedc4aa82d5b35cb.png | complex | <table><tr><td rowspan="2">Bacteria</td><td colspan="4">MIC (mg/mL)</td></tr><tr><td>IxPE</td><td>IxCE</td><td>IxME</td><td>IxWE</td></tr><tr><td><i>Bacillus subtilis </i>(MTCC111)</td><td>2</td><td>>2</td><td>0.125</td><td>1</td></tr><tr><td><i>Staphylococcus aureus </i>(MTCC3160)</td><td>>2</td><td>>2</td><td>1</td><td>>2</td></tr><tr><td><i>Streptococcus mutant</i> (MTCC890)</td><td>>2</td><td>1</td><td>2</td><td>2</td></tr><tr><td><i>Escherichia coli </i>(MTCC443)</td><td>2</td><td>1</td><td>2</td><td>>2</td></tr><tr><td><i>Klebsiella pneumoniae </i>(MTCC109)</td><td>>2</td><td>>2</td><td>0.25</td><td>>2</td></tr><tr><td><i>Pseudomonas aeruginosa</i> (MTCC741)</td><td>2</td><td>2</td><td>0.5</td><td>2</td></tr></table> |
11cb9c18a9babdd9a2d9dc17981242367f7f610b08908c5a76113651434f7f11.png | simple | <table><tr><td></td><td>Current wheeze</td><td>Ever had wheeze</td><td>Wheeze disturb sleep</td><td>Wheeze limiting speech</td><td>Exercise wheeze</td><td>Night cough</td><td>Ever had asthma</td><td>Any asthma symptoms</td></tr><tr><td>Boys</td><td>29 (9.0%)</td><td>75 (25.3%)</td><td>3 (3.8%)</td><td>4 (4.8%)</td><td>14 (4.8%)</td><td>44 (14.9%)</td><td>43 (13.3%)</td><td>89 (27.6%)</td></tr><tr><td>Girls</td><td>22 (5.8%)</td><td>65 (18.5%)</td><td>8 (11.6%)</td><td>4 (5.48%)</td><td>15 (4.3%)</td><td>38 (11.0%)</td><td>31 (8.2%)</td><td>77 (20.4%)</td></tr><tr><td>Overall</td><td>51 (7.3%)</td><td>140 (21.6%)</td><td>11 (7.4%)</td><td>8 (5.1%)</td><td>29 (4.5%)</td><td>82 (12.8%)</td><td>74 (10.6%)</td><td>166 (23.7%)</td></tr></table> |
eb336ad349a869dec796b92c4a1cab63b9980beee5db78f375e5fa8e3be4ee5d.png | simple | <table><tr><td> </td><td>Units</td><td>CN</td><td>MCI</td><td>AD</td><td>P-value</td></tr><tr><td>n</td><td>—</td><td>91</td><td>144</td><td>67</td><td>NA</td></tr><tr><td>Age</td><td>Years (s.d.)</td><td>75.74 (5.43)</td><td>74.85 (7.2)</td><td>74.57 (7.61)</td><td>0.502</td></tr><tr><td>Female</td><td><i>n</i> (%)</td><td>46 (50.55)</td><td>47 (32.64)</td><td>29 (43.28)</td><td><i>0</i>.<i>021</i></td></tr><tr><td>Education</td><td>Years (s.d.)</td><td>15.67 (2.94)</td><td>15.91 (2.95)</td><td>15.01 (2.96)</td><td>0.123</td></tr><tr><td><i>APOE</i>-ɛ4 +ve</td><td><i>n</i> (%)</td><td>22 (24.18)</td><td>75 (52.08)</td><td>46 (68.66)</td><td><i>6.50 × 10</i><sup><i>−8</i></sup></td></tr><tr><td>ADAS-Cog13</td><td>Units (s.d.)</td><td>9.51 (4.16)</td><td>19.19 (5.94)</td><td>29.22 (8.21)</td><td><i>2.75 × 10</i><sup><i>−56</i></sup></td></tr><tr><td>CSF Ferritin</td><td>ng ml<sup>−1</sup> (s.d.)</td><td>6.4 (2.07)</td><td>6.95 (2.72)</td><td>6.94 (2.99)</td><td>0.591</td></tr><tr><td>CSF ApoE</td><td>μg ml<sup>−1</sup> (s.d.)</td><td>7.3 (2.21)</td><td>7.1 (2.22)</td><td>6.35 (2.27)</td><td><i>0.012</i></td></tr><tr><td>CSF tau</td><td>pg ml<sup>−1</sup> (s.d.)</td><td>69.78 (28.01)</td><td>104.3 (52.41)</td><td>122.63 (57.47)</td><td><i>4.57 × 10</i><sup><i>−7</i></sup></td></tr><tr><td>CSF ptau</td><td>pg ml<sup>−1</sup> (s.d.)</td><td>24.77 (13.34)</td><td>36.39 (16.09)</td><td>41.39 (20.76)</td><td><i>1.13 × 10</i><sup><i>−6</i></sup></td></tr><tr><td>CSF Aβ<sub>1-42</sub></td><td>pg ml<sup>−1</sup> (s.d.)</td><td>205.31 (56.38)</td><td>161.06 (52.06)</td><td>142.16 (36.84)</td><td><i>2.29 × 10</i><sup><i>−6</i></sup></td></tr><tr><td>CSF tau/Aβ<sub>1–42</sub></td><td>Units (s.d.)</td><td>0.39 (0.26)</td><td>0.75 (0.5)</td><td>0.94 (0.52)</td><td><i>7</i>.<i>80 × 10</i><sup><i>−9</i></sup></td></tr><tr><td>Hippocampus</td><td>mm<sup>3</sup> (s.d.)</td><td>7,219.6 (848.6)</td><td>6,230.9 (1,047.8)</td><td>5.766.6 (1,283.2)</td><td><i>6.71 × 10</i><sup><i>−20</i></sup></td></tr><tr><td>Lateral ventricle</td><td>mm<sup>3</sup> (s.d.)</td><td>34,052.62 (16,528.1)</td><td>44,842.52 (23,574.05)</td><td>49,902.53 (26,896.68)</td><td><i>3.35 × 10</i><sup><i>−5</i></sup></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.